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Supervisors: George Georgiou and Brent Iverson 
 
Monoclonal antibodies have become essential therapeutic tools and currently 
dominate the therapeutic protein market. Consequently, there is continued demand for 
new therapeutic antibodies and their discovery techniques. 
In one part of this work, we report the discovery of a new therapeutic antibody 
candidate with a novel mechanism for inhibition of a therapeutically relevant biochemical 
pathway: the classical complement pathway. In order to inhibit classical complement, an 
antibody was developed that modulates the signaling subcomponent of the pathway 
initiating C1 complex, C1s. This work includes novel protocols and strategies used for 
discovery and characterization of antibody D, which binds and inhibits C1s protease 
activity. By regulating C1s activity, antibody D is shown to regulate classical 
complement. It is further shown that affinity maturation of antibody D results in higher 
levels of complement inhibition at various antibody concentrations. This work marks the 
first example of an antibody that specifically regulates the classical complement pathway 
by targeting the C1s protease on the pathway initiating C1-complex.  
 Next, we characterize the human immune cells produced by humanized NSG 
mice, most notably the B and T lymphocytes, engraftment with human CD34+ HSC cells. 
We detected development of naïve human B and T cells and their various subtypes, as 
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well as other human immune cells from engrafted mice. However, attempts to generate a 
robust antibody response to antigens were unsuccessful. Therefore, we conclude that 
NSG humanized mice developed in this study are suitable for studying the antibody 
repertoire of naïve B cells, however they are not suitable for the analysis of activated B-
cells.  
Last, we introduce a novel strategy for the generation of polarized antibody 
repertoires for use in therapeutic monoclonal antibody discovery. This technique 
combines targeted antigen delivery to a specific lymph node and a frequency based 
antibody selection approach in order to directly select antigen specific antibodies in 
silico. By directly selecting antigen-specific antibodies, this approach circumvents 
laborious and time consuming screening techniques. We expect that this work will be the 
foundation of an overall improved protocol for monoclonal antibody discovery that 
accelerates the speed and enhances the simplicity of discovery techniques.  
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Chapter 1. 
  Engineering Antibodies 
 
INTRODUCTION 
Humans are under constant threat from a vast array of infectious agents. The skin 
and mucosal membrane act together as the primary barrier to keeping pathogens at bay; 
their function is to serve as a physical barrier keeping pathogens from gaining entry into 
the body. However, these barriers are occasionally breached by disease -causing pathogens 
leading to an infection and activation of the immune system. The immune system is 
composed of serum proteins, cells, tissues and organs that act in concert to detect, 
neutralize and dispose of invading pathogens.  Pathogens, in turn, are quick to evolve to 
avoid detection and escape the immune system.  In order to combat the vast array of ever 
evolving pathogens attempting to gain a foothold in the body, the immune system employs 
two general strategies to recognize pathogens and mark them for destruction: (1) recognize 
common features of invading organisms and (2) develop new receptors that recognize the 
unique features of a specific invading organism. The components that comprise the former 
non-specific strategy collectively form what is called the innate immune response and the 
components of the latter highly specific strategy form the adaptive immune response (1).  
The innate immune response is initiated when common features of invading 
pathogens are recognized by pattern recognition receptors (PRRs) on secreted serum 
proteins or the surface of cells such as phagocytes and granulocytes (2, 3).  PRRs on the 
phagocytes (primarily macrophages and neutrophils) are often the first to recognize an 
invading microorganism.  Once recognition of the microorganism has occurred, the 
phagocytes quickly internalize and destroy the invaders. Occasionally a microorganism is 
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able to overcome innate immune defenses and avoid destruction by the phagocytes. The 
ability to escape the initial innate immune response distinguishes pathogenic from non-
pathogenic microorganisms. Once a pathogenic microorganism gains a foothold in the 
body, macrophages and other cells of the innate immune system secrete chemokines and 
cytokines to stimulate both inflammation and antigen presentation by the phagocytes, thus 
initiating the adaptive immune response (4).  
The innate immune system is limited because it can only control pathogens that 
express a limited set of molecules with defined molecular patterns that are distinct from 
those of the macromolecules expressed by the host. In order to control a much wider range 
of pathogens, the adaptive immune system has evolved to recognize a far greater breadth 
of molecules (antigens) expressed by invading pathogens. Importantly adaptive immunity 
displays memory in that re-exposure to antigen decades later elicits a strong humoral 
immune response very quickly involving host molecules that are largely derived from 
those induced by the first exposure (5).  
The adaptive immune response is further divided into two components: humoral 
immunity and cell-mediated immunity. The cell-mediated aspect of the adaptive immune 
response involves T-lymphocytes that are able to either induce apoptosis in host cells 
displaying epitopes of foreign antigen on their surface (cytotoxic T cells) or assist other 
immunological processes, including the maturation of B cells into memory B cells and 
plasma cells and activating cytotoxic T cells and macrophages (6). Secreted 
immunoglobulins, known as antibodies, comprise the humoral aspect of the adaptive 
immune response.  
Antigens are recognized with low affinity by immunoglobulins expressed on the 
surface of naïve (non-antigen stimulated) B cells. B-cells displaying antigen-recognizing 
immunoglobulins undergo expansion and differentiation, eventually resulting in antibodies 
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with very high affinity and selectivity that are  secreted by terminally differentiated form 
of B cells, called plasma cells (7). Antibodies differ from the innate immune PRRs in that 
each antibody has been selected to target a specific antigen with high specificity in order to 
help control the pathogen that expresses that particular antigen. Antibodies are very stable 
proteins and have a long half-life with some isotypes capable of remaining in circulation 
for up to three weeks (8).   By comparison, proteins other than antibodies having the same 
molecular weight and charge are removed from circulation within 1-3 days.  Once bound 
to an antigen, antibodies confer protection through three pathways: neutralization of the 
pathogen which is prevented from infecting the host, activation of complement 
(complement dependent cytotoxicity, CDC), and recruitment of phagocytes for 
opsonization (antibody dependent cell cytotoxicity, ADCC) (9). Antibodies can recognize 
a wide variety of antigens including proteins, small molecules, lipids, carbohydrates and 
nucleic acids.  
Antibodies have become widely utilized as therapeutics and thus antibody 
discovery and engineering have evolved into a multi-billion dollar industry. The first FDA 
approved clinical use of an antibody in humans occurred in 1982 (muromonab, a mouse 
IgG used as an immunosuppressant; it destroys human T cells by binding surface antigen 
CD3), and in 1997 the first anticancer antibody received approval (rituximab, a chimeric 
antibody that binds to the B cell surface marker CD20; it is used to treat diseases 
characterized by excessive B cells such as lymphomas) (10).  As of May 2012, there were 
39 monoclonal antibodies approved by the FDA (fda.gov, list below). The impact of 
antibody therapeutics is specifically demonstrated by the fact that they have generated 
~$18.5 billion in sales for 2010, the highest of all biological drugs (11). Their importance 
in diagnostics and therapy cannot be understated.  
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#	   Trade	  Name	   mAb	   #	   Trade	  Name	   mAb	  
1	  
Orthoclone	  
OKT3	   Muromonab-CD3  21	  
PROSTASCIN
T	   CAPROMAB PENDETIDE 
2	   ACTEMRA	   TOCILIZUMAB 22	   RAPTIVA	   EFALIZUMAB 
3	   ADCETRIS	   BRENTUXIMAB VEDOTIN 23	   REMICADE	   INFLIXIMAB 
4	   ARZERRA	   OFATUMUMAB 24	   REOPRO	   ABCIXIMAB 
5	   AVASTIN	   BEVACIZUMAB 25	   RITUXAN	   RITUXIMAB 
6	   BENLYSTA	   BELIMUMAB 26	   SIMPONI	   GOLIMUMAB 
7	   BEXXAR	  
TOSITUMOMAB; IODINE I 131 
TOSITUMOMAB 27	   SIMULECT	   BASILIXIMAB 
8	   CAMPATH	   ALEMTUZUMAB 28	   SOLIRIS	   ECULIZUMAB 
9	   CEA-­‐SCAN	   ARCITUMOMAB 29	   STELARA	   USTEKINUMAB 
10	   CIMZIA	   CERTOLIZUMAB PEGOL 30	   SYNAGIS	   PALIVIZUMAB 
11	   DERMABET	   BETAMETHASONE VALERATE 31	  
TECHNETIU
M	  
TECHNETIUM (99m Tc) FANOLESOMAB; 
NEUTROSPEC 
12	   ERBITUX	   CETUXIMAB 32	   TYSABRI	   NATALIZUMAB 
13	   HEMABATE	   CARBOPROST TROMETHAMINE 33	   VECTIBIX	   PANITUMUMAB 
14	   HERCEPTIN	   TRASTUZUMAB 34	   VERLUMA	   NOFETUMOMAB 
15	   HUMIRA	   ADALIMUMAB 35	   XGEVA	   DENOSUMAB 
16	   ILARIS	   CANAKINUMAB 36	   XOLAIR	   OMALIZUMAB 
17	   LUCENTIS	   RANIBIZUMAB 37	   YERVOY	   IPILIMUMAB 
18	   MYLOTARG	   GEMTUZUMAB OZOGAMICIN 38	   ZENAPAX	   DACLIZUMAB 
19	   MYOSCINT	   IMCIROMAB PENTETATE 39	   ZEVALIN	   IBRITUMOMAB TIUXETAN 
20	   PROLIA	   DENOSUMAB 	  	   	  	   	  	  
Table 1.1: Current List of FDA Approved Monoclonal Antibodies (http://www.fda.gov/ 
May 2012) 
 
ANTIBODY STRUCTURE 
Antibodies are composed of two identical heavy and light chains that come 
together to form the “Y” shape molecule shown in the figure below. The heavy chain and 
light chains are organized into multiple immunoglobulin domains that are held together 
into their large complex by disulfide bonds.  
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Figure 1.1: Antibody domain structure (IgG) and antigen binding sites (12).  
An antibody monomer is comprised of two identical antigen-binding fragments 
(FAB); the antigen binding domains are linked together by the constant domain (Fc) that 
recruits immune cells to dispose of the bound antigen.  In the human immune system, there 
are different constant domains and they define the respective isotypes: IgA, IgD, IgG, IgE, 
IgM. Each isotype has a different Fc domain structure that controls the types of effector 
cells that can be recruited by the antibody, whether the antibody can activate the 
complement pathway and avidity. The most common isotype in serum and the only one 
used therapeutically so far is IgG (13). IgA and IgG isotypes are further divided into 
subclasses (IgG1, IgG2, IgG3, IgG4 and IgA1 and IgA2). The subclasses are >95% 
homologous but differ in their ability to activate effector responses.  
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Figure 1.2: Structural comparisons of antibody isotype and subclass and their relative 
chromosome location (1) 
Each antibody has two identical fAb fragments composed of two light chain and 
heavy chain immunoglobulin domains. The antigen-binding site is located within the 
variable domain at the N terminus of each chain; each variable domain contains three 
complementary determining regions (CDRs) that establish antigen binding. The heavy and 
light variable regions of the antibody come together to create the complete antigen-binding 
site.    
 
Antigen Recognition and the Variable Domains 
The antibody antigen binding sites are found within the first globular protein 
domain on the N terminus of the heavy and light chains. These antigen recognition 
domains are called variable domains because of the vast diversity of peptide sequences 
found within these domains. The majority of the diversity in each variable domain occurs 
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at the antigen binding loops are called the complementary determining regions (CDRs) or 
hyper variable regions.   
 
Figure 1.3: A variability plot derived from the amino acid sequences of several dozen 
heavy and light chain V domains is shown. The red areas of higher variability 
are the CDRs (1) 
Both the heavy and light chain have three CDR loops giving each fAb arm six 
CDRs with which to bind one antigen epitope. The third CDR of the heavy chain, termed 
the CDRH3, is the most variable CDR loop and the most significant loop in determining 
binding specificity. The CDRH3 is so diverse because it is formed at the junction of the 
genetic recombination of the three different fragments, named the heavy chain V, D and J 
regions (14). The human genome has many V, D and J regions that can recombine during 
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B cell development in order to produce many different functional heavy chains (14). 
Besides combining three different immunoglobulin gene segments, the mechanism of 
genetic recombination also stochastically introduces additional diversity by adding or 
deleting nucleotides.  This recombination event can produce a near CDH3 infinite diversity 
at the site.  
The two other CDR loops found on the heavy chain are not the product of a 
recombination event; therefore the number of germline V gene fragments determines the 
initial diversity of these loops. However, through a mechanism called somatic 
hypermutation, these loops are often mutated in order to increase the affinity of the 
antibody. The light chain forms in a similar manner except that it is the product of a 
recombination event that has only two genetic fragments, termed light chain V and J 
fragments. Because the light chain CDRL3 is the product of only two genetic fragments 
coming together, there is significantly less diversity.  
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Figure 1.4: V gene construction from V-region gene segments (1). 
 
Antibody Effector Function 
Antibodies interact with the innate immune system through the Fc (constant region) 
portion of the antibody. The FC interacts with the host environment and the innate immune 
system in three main ways: (1) By binding cell surface receptors on innate immune cells to 
induce reactions critical for pathogen clearance. (2) By initiating the cytolytic cascade of 
serum protein activation collectively known as the classical complement pathway. This 
interaction beings when the FC interacts with the pathway initiating C1 complex binding; 
antibody activation of this process is referred to as CDC, complement dependent 
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cytotoxicity. (3) Mediating the presentation of antigens to dendritic cells and other innate 
immune cells that in turn trigger adaptive immune responses to the pathogen.  
The various antibody isotypes and subclasses have different affinities for Fc 
receptors and C1 complex. The avidity and interaction between the Fc and cell surface 
receptors or serum proteins determines the nature of the response elicited by the 
complement pathway or by effector cells. For example, human IgG4 cannot bind C1 
complex while the other three IgG subclasses can.  
 
 
Figure 1.5: Outline of effector functions dependent on antibody Fc. ADCC(a), CDC (b) 
and FcRn binding are shown. Phagocytosis is not shown (9)  
Present on most cells of the immune system are Fc receptors (FcRs) that bind the 
constant region (Fc) of specific immunoglobulin (Ig) isotypes and isotype subclasses. 
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Different cells express different FcRs depending on the function of the cells and the Igs to 
which they respond. Cellular internal signaling cascades initiated by immune complexes 
that bind the FcRs are commonly activating signals that result in phagocytosis of the 
immune complex that initiated the signal. In other cases, activation of mast cells can lead 
to an allergic reaction when IgE binds its receptor, while activation on NK cells by IgG 
leads to release of its granules. One IgG molecule is insufficient to activate FcγRs (IgG 
binding FcRs). Instead, the key to signal transduction is the cross-linking of receptors by 
immune complex. After the pathogen is bound by the Fc receptors of the phagocyte, the 
pathogen is ingested and destroyed by the in a process called phagocytosis. 
FcRs on non-phagocytes can actively destroy target pathogens through a different 
mechanism know as antibody dependent cell cytotoxicity (ADCC). ADCC is a process in 
which effector cells lyse a target cell coated in antibody without engulfing or ingesting, a 
process primarily carried out by natural killer cells (NK), ADCC occurs when the FcR 
expressed on NK cells (called FcγRIII) binds to immune complexes formed by pathogen 
and antibodies bound to it (15). Upon activation by immune complexes, NK cells secrete 
cytokines and cytotoxic granules that enter the pathogen and promote cell death and 
apoptosis.  
Another very important function of the Fc region is to increase the serum half-life 
and aid in the transport of antibodies across cellular barriers by interacting with the 
neonatal Fc receptor (FcRn) (16, 17). FcRn is presented on a many different cell types, 
including the endothelial cells that form the interior surface of the blood and lymphatic 
vessels. The FcRn prolongs in vivo half-life by binding IgG that has been ingested into an 
acidified endosome via non-specific vesicle mediated uptake of fluid by the cell. Once 
bound, IgG is recycled back to the cell surface where it is released in the mildly basic pH 
of blood, thereby preventing it from undergoing degradation in the endosome. Without 
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FcRn binding ability, the half-life of antibodies is reduced dramatically from 21 days to 7 
(18, 19).  
 
Classical Complement Pathway 
Antibodies also engage the complement system in order to eliminate pathogens and 
toxins. The complement pathway system is a complex and powerful component of the 
immune system that is essential for proper clearance of immune complexes and apoptotic 
or damaged cells. The complement system is made up of a large number of plasma 
proteins that cooperate via a biochemical cascade to destroy a pathogen and induce an 
inflammatory response that helps fight infection. Complement is organized into three semi-
independent pathways (classical, alternative and lectin), each of which is activated by 
different physiological conditions. Any one or more of the three pathways shown in the 
figure 1.16 can activate the complement cascade. Once a pathway is activated, a 
biochemical cascade is initiated by the activation of a zymogen protease (inactive) that 
cleaves and activates the next zymogen substrate in order to propagate and continue the 
cascade. Complement is an autocatalytic process, therefore activation of a pathway leads to 
the pathogen surface being coated with complement defense proteins that mark it for 
destruction and provide a signal for removal by immune cells.  
One route that activates this process, called the classical complement pathway, 
occurs when complement proteins recognize a pathogen coated with antibodies. The 
classical complement protein complex C1 binds the either the C-reactive protein (CRP) or 
the Fc region of IgM or IgG1-3 initiates an attack on the pathogen. This pathway 
ultimately results in the formation of membrane attack complexes (MACs) that disrupt the 
phospholipid bilayer on a target cell, resulting in cell lysis and death.  In addition to 
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MACs, the complement pathway also deposits a protein called C3b on the surfaces of 
target cells, which promotes their destruction by phagocytosis. Complement activation also 
results in the release of cytokine-like molecules C5a and C3a, which results in chemotaxis 
and activation of leukocytes.  
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Figure 1.6: Complement overview: the classical (red), lectin (blue) and alternative (purple) 
pathways are initiated by different protein complexes that recognize different 
conditions, but the pathways ultimately use the same downstream proteins 
(20)   
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The classical complement pathway is comprised of nine protein complexes, yet 
only the pathway-initiating C1 complex is an exclusive member of the pathway. Whereas 
the other complement pathways – lectin and alternative - share the other constitutive 
proteins found in the classical pathway. Thus, targeting the initiation complex (C1) for 
intervention and inhibition of classical complement is the logical option to control this 
pathway without adverse consequences to the other essential pathways.  
The function of C1 complex is to first recognize physiological conditions for 
activation of complement and then begin the classical complement cascade. It is composed 
of one C1q molecule with six terminal C1q globular heads, which recognize initiation 
conditions, two C1r proteases that activate C1s upon initiation, and two C1s proteases that 
transmit the activation signal by cleaving serum complement components C2 and C4 (21). 
Classical complement pathway begins when C1q globular heads recognize surface bound 
IgG, IgM or C-reactive protein (CRP) then undergo a conformational change. These 
conformational changes induce C1r to self-activate, which in turn activates C1s, the 
protease that propagates the activation signal to other serum proteins.  
   
 
Figure 1.7: C1s in complex with C1q and C1r while recognizing IgG (22) 
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C1s is a 75kDa serine protease with an identical domain organization to C1r and 
MASP-1, MASP -2, and MASP -3 of the complement lectin pathway of complement 
activation(23). Each member of this family is composed of five non-catalytic domains 
followed by a C terminal chymotryipsin-like serine protease domain. 
 
Development of B cells 
Immature B cells are produced in the bone marrow, where V(D)J recombination 
occurs and self-reactive B cells are apoptosed (here called clonal deletion). Immature 
IgM+/IgD- B cells travel from the bone marrow and travel through the blood to the spleen; 
once in the spleen, they are subjected to further rounds of clonal deletion before becoming 
fully mature (24). In the presence of a supporting microenvironment, immature B cells 
become mature long-lived naïve B cells (follicular B cells) and recirculate through 
secondary lymphoid organs in search of signs of infection (25). A small number 
developing B cells become immobile marginal zone (MZ) B cells instead of follicular B 
cells; the decision to become a MZ B cell is though thought to be in part related to the 
strength of B cell receptor signaling (26). MZ B cells home to the spleen and can be 
activated in a T-cell independent manner. Follicular B cells are the most common naïve B 
cell and they home primarily to B cell follicles in the secondary lymphoid organs. B cell 
follicles are always located in secondary lymphoid organs near T cell zones, an 
arrangement that allows for activated T helper cells to quickly activate follicular B cells 
that have bound antigen.  
Once follicular B cells are activated by T helper cells and antigen recognition, they 
can proliferate and differentiate to form either plasma cells capable of antibody secretion 
or memory cells that provide long lived memory against subsequent infections (27). Most 
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plasma cells generated upon activation of naïve B cells are short lived plasma cells that 
primarily remain in the extramedullary region on the secondary lymphoid organ (28); a 
small fraction become long lived plasma cells primarily home to the bone marrow where 
they can persist for many years. Activated B cells can also travel to the germinal centers 
(GC) where GC reactions provide a cellular milieu for the mutation and affinity maturation 
of the B cells (25).  
  
Recombinant Antibody Fragments 
Advances in molecular cloning techniques have enabled the production of antibody 
variable domains without the constant region domains. Antibody variable domains are the 
only domains required for antigen binding.  
 The most common host for heterologous expression of antibody genes is E. coli. 
Expression of full-length antibodies is relatively more difficult and can result in the 
production of an appreciable amount of misfolded protein. Therefore for bacterial 
expression antibody fragments, namely fAb, scFv or scAb formats (see figure below) are 
much more widely employed. Antibodies in scFv format comprise only the variable heavy 
and light domains linked by a short peptide sequence. Fab antibodies consist of the entire 
VL chain and the variable heavy as well as the first constant region of the VH. A disulfide 
bond in the constant regions is responsible for linking FAB heavy and light chains. 
Additional formats are shown in the figure blow. Multivalent antibody fragments are 
occasionally desirable because they provide an increase in functional affinity (avidity) or 
can be engineered to have multiple specificities(29, 30).  
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Figure 1.8: Representative antibody formats created through genetic manipulation and 
protein expression (12). Constant regions are purple, heavy chains are green, 
light chains are orange, and sugars are blue. scAbs are important in this study, 
they are scFvs with the light chain constant domain C-kappa attached at the 
C-terminus of the peptide. 
ANTIBODY SPECIFICITY AND AFFINITY 
As discussed above, the antigen-binding site of antibodies lies within the variable 
region. The specific residues on an antigen that interact with amino acids in the antigen-
binding site of the antibody constitute the binding epitope. The two most important 
characteristics of an antibody Fab region are its specificity and affinity for the epitope it 
binds. Specificity is the ability of the Fab region to recognize and bind one antigen over 
another. An antibody that binds and forms an immune complex with many similar epitopes 
is said to have “poor specificity”. Conversely, an antibody that binds one antigen epitope 
but will not bind another highly similar epitope is said to have “high specificity”.   
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Antigen affinity is often used as the standard quantitative measure of the quality of 
an antibody. The affinity of the Fab region for an antigen can be generally thought of as 
the “tightness” of the interaction. In order to numerically define affinity, first it is 
necessary to desirable the interaction in a quantitative way. The formation of immune 
complexes is a reversible process, therefore the formation of immune complex can be 
written as the following: 𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦 + 𝐴𝑛𝑡𝑖𝑔𝑒𝑛 ⟷ [𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦:𝐴𝑛𝑡𝑖𝑔𝑒𝑛] 
The association rate (forward reaction) is governed by the rate constant kon      (M-
1s-1) and the dissociate rate (reverse reaction) is governed by the off rate constant koff (s-1). 
These rates are dependent on the concentration of the antibody and antigen, but reach the 
same values at equilibrium; at that point the concentrations of the complex, antibody and 
antigen are constant. Once the reaction reaches equilibrium, the ratio between immune 
complex and the separated component parts is constant and can be written in the following 
manner: 
 𝐾! = 𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦 [𝐴𝑛𝑡𝑖𝑔𝑒𝑛][𝐴𝑛𝑡𝑖𝑏𝑜𝑑𝑦:𝐴𝑛𝑡𝑖𝑔𝑒𝑛] = 𝑘on𝑘off 
 
The constant KD, called the dissociation constant, is the most common measure of 
antibody affinity. The smaller the dissociation constant, the greater the propensity for the 
antibody to be in complex with antigen; thus smaller dissociation constants are indicative 
of tighter bonds between antigen and antibody. There are various methods for determining 
the dissociation constant and the individual rate constants. Two important technologies for 
determining the dissociation constant considered here are surface plasmon resonance and 
kinetic exclusion assay.  
 20 
 
Surface Plasmon Resonance (BIACore) 
SPR is the most popular way to measure the equilibrium dissociation constant and 
kinetic parameters for two interacting molecules. The most attractive feature of this 
technology is that does not require a secondary probe or fluorophore conjugate in order to 
detect an interaction; therefore SPR is free from the compilations that can arise from the 
labeling of molecules. The most popular instrument used for SPR is BIACore. BIACore 
and other similar SPR instruments are microfluidic devices that immobilize one of the 
binding partners on the surface of a sensor chip then flow the other binding partner over 
the surface. When an interaction occurs between the fluid phase and immobilized binding 
partners, there is a slight change in mass on the surface of the chip. This minuscule change 
in mass is monitored by a change in the reflected light directed at the other side of the chip. 
The greater the change in mass, the higher the deflection of the reflected light. The 
measure of the change in mass near the surface is used to create a real-time interaction 
profile called the sensorgram. One such example of a sensorgram is shown in the figure 
below. In an experiment, many of these sensorgrams are generated using different 
concentrations of unbound material followed by interpretation  of results via mathematical 
software order to calculate the equilibrium dissociation constant KD, and the association 
and dissociation rates (kon and koff) 
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Figure 1.9: Schematic illustration of a sensorgram with bars below indicating the solution 
passing over the sensor surface. The x-axis is time and the y-axis is an 
aribtraty unit (RU) which correlates with the mass on the surface of the 
sensor. Extracted from BIACore handbook.  
 
Kinetic Exclusion Assay (KinExA) 
The kinetic exclusion assay experiment measures the equilibrium dissociation 
constant KD and association rate kon directly; multiplying the two experimental values 
together calculates the off rate. The advantage of this method is that equilibrium is 
measured with both components in the solution phase. Other technologies, such a SPR, 
require one of the components to be immobilized to a surface, which can distort and 
destabilize the delicate proteins.    
The most popular machine for running this sort of assay is called a KinExA. In 
order to determine the KD of an antibody, first one of the binding partners (usually the 
antigen) is immobilized to a solid bead support (usually through adsorption to polystyrene 
beads). Immobilized antigen is then used as a probe to capture the free component of the 
other partner (antibody) once equilibrium is reached between solution phase antibody and 
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antigen. This exposure time is quick enough that any antibody in a preformed complex 
with antigen in solution will not have the time needed for dissociation. A secondary 
antibody conjugated to a fluorophore is then used to detect antibody captured by the 
immobilized antigen for each solution of antibody and antigen.  
For each experiment, a series of solutions containing different concentrations of 
antigen and a constant concentration of antibody are equilibrated before being exposed to 
the solid phase antigen in order to capture free antibody. It is important to note that even 
though immobilized antigen is used as a capture agent, equilibrium is still being measured 
from liquid phase interactions.  
 
 
Figure 1.10: Steps involved in kinetic exclusion assay and representative signal output. R= 
receptor (antibody), L= ligand (antigen), LR=ligand-receptor complex. 1. 
Immobolized antigen (L) is loaded into the detection well. 2. Antigen 
antibody mixture at equilibrium is flown over the beads. The beads capture 
antibody not in complex with antigen, but antibody in complex is not. 3. 
Secondary fluorescent probe is flown over beads 4. Buffer is run over beads, 
leaving only bound secondary probe. Extracted from the KinExA guidebook. 
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In each experiment, output signals are measured from a series of solutions with 
different antigen concentrations and a constant antibody concentration. After a series is 
measured in duplicate, mathematical software calculated the dissociation constant KD. 
Binding kinetics can be determined by further experiments in which the measurements are 
collected “pre-equilibrium”.  
 
 
THERAPEUTIC ANTIBODIES AND THEIR DISCOVERY 
Antibody therapy in humans began in the 1890s when Emil von Behring and 
colleagues discovered that transferring serum from animals immunized with diphtheria 
could protect humans from the same disease (31). At the time they did not know the 
protection was a result of the antibody transfer, so they named this processes “serum 
therapy”. Serum therapy brought with it significant complications because antibodies could 
not be separated from the serum, resulting in intense immune reactions to the foreign 
serum proteins. Over time, purification of the antibody fraction became possible; however 
this fraction was still very impure by modern standards because it contained both 
unintended antibodies and other with impurities that could not be removed. During the 
early 1900s, advances in vaccination and antibiotics would largely overshadow this 
technology (32). It was not until the mid 1970s that antibody technology would see its next 
major advance: a breakthrough technology that enabled the mass production of a single 
antibody clone.  
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Hybridoma Technology 
In the mid-1970s an important breakthrough occurred, which would be known as 
the beginning of modern antibody engineering: hybridoma technology (33). Before the 
advent of the hybridoma method, investigators could only produce polyclonal serum 
antibodies; this required large numbers of immunized animals and did not immortalize the 
antibody-producing cells. Therefore production was a cumbersome process requiring many 
animals in order to produce more antibodies and each preparation was different that the 
one before. To overcome this problem, a technology was needed that could produce an 
infinite number of the same antibody. The easiest solution was to extract one of the 
antibody-secreting lymphocytes from immunized animal and grow it indefinitely in 
culture, however antibody-secreting cells have a finite lifespan and will not continue living 
or dividing in culture for very long. In order to overcome this limitation, Köhler and 
Millstein developed a method to create an antibody producing cell line capable of dividing 
and living indefinitely outside of an animal; these cultures produced a near infinite amount 
of the same monoclonal antibody clone (mAbs) (33). The two scientists achieved this feat 
by fusing antibody-secreting lymphocytes with myeloma cells; the resulting cell was a sort 
of cancer cell that would grow indefinitely in culture while producing only one type of 
antibody (34). These fusion cells are called hybridomas.  
Hybridomas can now be created in most any biological lab today. Production of a 
monoclonal hybridoma cell line requires a multistep protocol that can take months in order 
to create cell line producing an antibody specific to an antigen. The first step necessary is 
to immunize mice with antigen followed by B-cell isolation from the spleen or other 
lymphocyte-containing anatomical locations. B cells are then pooled with mouse myeloma 
cells that do not secrete antibody before being incubated in media that promotes cellular 
fusion. The fusion process is stochastic and results in B-cell / B-cell, B-cell / myeloma 
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(hybridoma), and myeloma / myeloma products. The B-cell / B-cell product and single B 
cells do not survive long, and due to a key genetic mutation, the myeloma cells that have 
not fused with a B-cell will eventually die in the presence of aminopterin. Therefore after 
culturing in aminopterin, the only surviving cells have are a fusion of at least one B-cell 
and myeloma cell. The surviving hybridomas are then diluted into single cell 
compartments where they grow indefinitely and produce antibodies. The antibody-
containing supernatant is assayed for specificity to the antigen desired, and wells 
containing antigen-specific antibodies have successful hybridomas that are expanded, 
cultured and further characterized.  
The hybridoma technique remained the dominant method for discovering and 
expressing monoclonal antibodies for a long time and is still commonly used to in industry 
today. However, this technology is not without drawbacks; the process in very long. It can 
take month to immunize mice, wait for an appropriate immune response, then create and 
expand the hybridomas. Competing technologies such as phage display with a synthetic 
library (discussed in subsequent sections) offer antibody isolation in weeks. Furthermore, 
hybridoma produced antibodies commonly have sub-optimal dissociation constants, 
because the murine antibodies isolated from hybridoma technology often have roughly 
nano-molar range dissociation constants while many therapeutic antibodies today have 
pico-molar constants (12, 35, 36). Affinity maturation is often required in order to have a 
therapeutically relevant antibody. Another complicating factor associated with antibodies 
produced from hybridomas is that murine Fc regions are not readily recognized by human 
FcRs. As a result, mouse antibodies are not very effective at soliciting a response from 
human effector cells. The most significant drawback of therapeutic antibodies produced 
from hybridomas is their immunogenicity (37).  Antibodies produced from mice are often 
recognized by the human immune system as foreign. Therefore after repeated treatments, 
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the immune system mounts an immune response that fights against the foreign antibodies, 
a process known as human anti-mouse antibody (HAMA) response.  
 
Humanized Antibodies 
In order to circumvent complications associated with injecting murine antibodies 
into humans, antibodies with a human framework were necessary. Only very recently have 
reports of human hybridomas become a seemingly viable technology; however there are 
still many technical and ethical issues limiting their widespread adoption (38, 39). Instead 
the first and still most common solution was to produce human-like antibodies from mice. 
This was first accomplished by linking the variable domains found using hybridoma 
technology to the constant domains of human antibodies. These murine-human antibody 
chimeras remove much of the murine sequence, resulting in less immunogenicity and 
engagement of the human FcRs. The FDA has approved several chimeric antibodies, 
however the remaining murine sequences still result in HAMA response (40).  
The immunogenicity of chimeric antibodies has been further reduced by continued 
humanization. The next iteration of antibody humanization is to further reduce the amount 
of murine antibody sequence by CDR grafting. In this process the murine CDR loops that 
bind the antigen are grafted onto human variable frameworks (41). This produces an 
antibody with even less murine sequences, resulting in less frequent and less severe 
immunogenicity. CDR grafting also has drawbacks: the human variable frameworks 
supporting the CDR loops are not identical to the supporting mouse framework; therefore 
when CDR loops are grafted onto different frameworks, they are not necessarily displayed 
in the same way. The consequence of the different frameworks is that CDR grafted 
antibodies often have a significantly reduced affinity for the antigen. Additionally these 
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loops are oftentimes slightly immunogenic, however, much less so than chimeric 
antibodies. Despite these problems, CDR grafted humanized antibodies are the most 
common type of FDA approved antibody.  
 
Human Antibodies from Mice 
Creating fully human antibodies is one of the most important goals in the field of 
antibody engineering for therapeutic purposes, but the obvious ethical and practical 
considerations of using humans for production prevent any direct methods for being 
employed. There have been advances in creating human hybridomas, however the use of 
this technology is still limited in application(38, 39, 42). Instead, a few very cleaver 
indirect methods have been devised to create fully human antibodies in mice.  
 
Transgenic Mice 
The most commonly explored method for attaining human antibodies from mice is 
through proprietary transgenic mouse models (or transchromosomic), meaning mouse 
immunoglobulin genes have been inactivated and replaced by human immunoglobulin 
variable and constant regions. This technology has proven extremely effective at producing 
human antibodies, as evidenced by all four of the clinically approved antibodies in 2009 
came from such transgenic mice(43). Examples of this technology include: 
 
Medarex - UltiMab platform 
Abgenix - Xenomouse technology. (acquired in April 2006 by Amgen) 
Regeneron - VelocImmune technology 
Kirin Brewery Co - Kirin TC Mouse  
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Humanized Mice 
The other technology that produces human antibodies from mice involves the 
engraftment of human hematopoietic cells or tissues in immuno-deficient mice. The 
advantage of this model is that it provides an opportunity to study human cells and 
biological processes in vivo (44). This is the model is significantly more difficult to use 
because engraftment requires expert training and engraftment levels are quite variable. 
Despite the inherent difficulties, this model pursued in studies today because it offers the 
rare opportunity to study fully human cells in vivo; therefore studies involving humanized 
mice have relevance to human immunology in addition to the therapeutic value of the 
antibodies produced from them.  
  Since the creation of the first humanized mice, increases in human 
lymphocyte populations and activity has been enabled by the systemic reduction of 
immune cells produced by the host mouse (45). Reduction in background immune cell 
production in the host is important to prevent competition with or rejection of human 
CD34+ cells once engrafted. One of the most popular mouse strains developed to date, and 
the one used in this research, is termed NSG (NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ mice). The 
genetic modifications introduced to this strain in order to reduce host immune function are 
the following:  
1. Non-obese-diabetic (NOD) – The genetic background derived from the 
NOD mouse line contributes reducing in innate immunity such as 
macrophage dysfunction, absent complement hemolytic activity, and 
reduced NK activity (46). 
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2. DNA-dependent protein kinase (Prkdc) – Commonly known as the severe 
combined immunodeficiency (SCID) mutation, this mutation results in 
inactive T cells and B cells (47). The PRKDC gene encodes a protein that 
resolves DNA strand breaks that occur during V(D)J recombination, 
resulting in significantly reduced numbers of T and B cells. 
3. IL-2 receptor γ chain – Disruption of the IL-2R common γ chain (γc) results 
in a loss of NK, B and T cells and dendritic cell dysfunction since γc is 
required for multiple cytokine signals that are indispensible to immune cell 
development (IL-2, IL-4, IL-7, IL-15, etc) (45) 
 
Additionally, exposing pups to 100cGy of gamma radiation 24-48 hours after birth 
ablates additional background immune cells and allows for optimal human HSC 
engraftment (48). Within 12 weeks of engraftment, the human CD34+ stem cells 
development a fully populated human immune system within the mouse (49-51). The 
development and effectiveness of the immune cell repertoire is sufficient and have to elicit 
a T and B cell response (50).  
The limitation of current humanized mice technologies such as the one described 
previously is that the B cell environment does not provide the appropriate cytokine signals 
in order to create numerous amounts of fully developed naïve B cells(52). This results in 
an immune repertoire that resembles a developing infant(53). In addition to further 
depleting the ability of the host to reject human cells, future progress in this field will focus 
on improving the cellular milieu of the mouse strains engrafted with human progenitors 
such that development, differentiation, and sustenance human lymphocyte population is 
better supported.  
 
 30 
In vitro Discovery Technologies 
Since its inception, hybridoma technology has been an essential method for 
discovering and expressing monoclonal antibodies and is still commonly used to in 
industry today. However, the process is very low throughput; it is not possible to screen 
large collections of antibody producing cells. In order to find the rare binding antibody 
from a pool of millions, major innovations were necessary. The collection of a large pool 
of antibody genes is called a library. Before the innovations enabling screening of large 
libraries could be established, essential molecular biology techniques would be required in 
order to create and express the libraries to be screened. Once the requisite tools were 
developed, they were used in many creative ways to build large antibody libraries and the 
systems used to discover the rare desirable clones.  
The many technologies invented for screening and sorting large antibody libraries 
are the topic of the following subsections. The first technology, called phage display, was 
invented first and is the most popular method.  After phage display technology, other 
screening platforms were developed that offered alternatives to the limitations of phage 
display screening. The common element each of screening platform possesses is the 
connection between genotype and phenotype(54). The type of link varies and each type 
link has unique advantages and disadvantages over the original phage technology. Each 
technology shares a common general methodology: enrichment of the library by applying 
selective pressure, amplification of the enriched population, and subjecting the enriched 
population to further rounds of selective pressure until the library is sufficiently enriched. 
The subsequent sections will focus on the many distinctive and creative ways to link 
genotype and phenotype and the screens or selections developed to discover antibodies 
from large libraries using the common strategy of applying iterative rounds of selective 
pressure.  
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Figure 1.11: Outline of the common process of discovering antibodies from large libraries 
of antibody genes for immune or synthetic sources (54). 
The processes and enabling technologies used to discover antibodies from large 
libraries can be broadly categorized as either screens or selections. Screens are processes 
that look at every individual within a library and keep only the desirable clones. Screens 
can be quite tedious and therefore very high throughput machines are employed to look at 
millions of clones quickly. Fluorescent Activated Cell Sorting (FACS) of cellular 
displayed antibodies is an example of a technique that utilizes a screening machine. 
Selections are methods that result in only desirable clones present when the selection is 
over, washing away unbound clones or selecting for a trait necessary for survival removes 
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the undesirable clones. An example of a selection the will be discussed in subsequent 
sections is phage panning.  
 
Figure 1.12: A condensed diagram depicting some of the many technologies linking 
genotype to phenotype (54). 
 
Phage Display Technology 
Once the requisite molecular cloning technologies became available, the first and 
most popular technique for discovering antibodies was established: phage display. In this 
screening technique antibody fragments are expressed on the surface of filamentous phage, 
a virus that infects only bacteria (55). This technology quickly became a routine method to 
isolate relevant antibodies from highly diverse libraries originating from a vast array of 
source genes (human, murine, naïve, immunized, or synthetic) (56-58). 
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Phage displaying antibodies on their surface are created in E. Coli. The most 
commonly used bacteriophage for phage panning are M13, fd and f1; the following 
explanation described M13 bacteriophage but other bacteriophages are highly similar (59). 
Each phage is made of two components: the genetic material and the protein coat. M13 
carries a genome that encodes 11 genes; five of these genes encode coat proteins displayed 
in the figure below, while the rest of the genes encode proteins necessary for viral 
assembly and replication.  
 
Figure 1.13: A representation of the proteins of a bacteriophage. Roman numerals and 
Arabic numerals are used interchangeably (60) 
The bacteriophage lifecycle begins when P3 binds the F pilus on the surface of the 
bacterial cell (61). Upon binding, the single stranded DNA (ssDNA) inside the 
bacteriophage is translocated into the bacterial cytoplasm. Once inside the cytoplasm, 
invading phage ssDNA is replicated, double stranded, and used as a template to create 
many phage particles. Before the assembly of a new phage particle, the coat proteins are 
embedded into the surface of the E. Coli inner membrane. P9 and P7 are the first of the 
coat proteins to be assembled into a new budding viral particle, followed by many 
thousands of P8 proteins. P8 proteins are continuously incorporated into an elongating 
phage until the bacteriophage genome is fully packaged into the budding particle, thus a 
bigger genome would result in a longer bacteriophage. P3 and P6 proteins are the last two 
proteins to be incorporated into the growing phage particle; once completed the assembled 
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phage particle is released into the extracellular environment. The budding of M13 phage is 
not a lytic process, therefore the infected bacteria will continue to grow and produce.  
Phage display technology manipulates the bacteriophage lifecycle in order to create 
hybrid phage particles that display antibodies on their surface and incorporate the antibody 
gene into the plasmid packaged within the particles. A plasmid that contains the necessary 
sequences for incorporation into a phage particle is called a phagemid. Hybrid phage can 
be produced a number of ways, the most common method fuses the antibody gene to an 
additional copy of the P3 phage protein. The antibody-P3 fusion is encoded by a phagemid 
that does not encode any of the other phage proteins but preferentially packages into new 
budding bacteriophage. In order to produce the other proteins required to create a new 
phage particle, an additional infection step is required with M13 helper phage. Helper 
phages have all the genetic information necessary to create a complete phage particle, 
however a mutation in the helper phage genome results in preferential packaging of the 
antibody containing phagemid instead of the helper phagemid into budding phage 
particles. Helper phage infection of an E. coli cell with an antibody-containing phagemid 
results in the production of hybrid phage with both an antibody displayed on the surface of 
the particle and the antibody gene incorporated within it; thus a link between antibody 
genotype-phenotype is established.  
 
Figure 1.14: A phage with antibody gene inside the coat and antibody fragments fused to 
the surface coat proteins (blue). Adapted from http://www.dyax.com/ 
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The ability to isolate the rare antibodies that bind an antigen of interest from a large 
library is accomplished by successive rounds of antibody selection, whereby the antibody 
population is repeatedly enriched for those that bind to an antigen of interest. For each 
round of selection, the phage-displayed-antibody library is incubated with an antigen 
immobilized to a surface (i.e. polystyrene or magnetic beads); unbound phage are washed 
away and bound phage are recovered for another round of screening, often this process is 
repeated for 3-8 rounds (62). Once successfully enriched, the library contains a large 
fraction of antibodies that bind the target antigen and relatively few clones (<100) need to 
be analyzed in order to isolate a binding antibody.  
 
 
Figure 1.15: An outline of phage display with antibody fAbs are displayed on the surface 
of phage (63). Multiple rounds of this process enrich phage displaying an 
antibody that binds the immobilized antigen.  
FACS and Surface Display Techniques 
Surface display is a technique used to select for proteins within large libraries with 
a desired characteristic. The technique requires the protein to be anchored to the surface of 
a cell in order to provide a link between genotype and phenotype (64, 65). A fluorescent 
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probe is then incubated with the cells and a florescent activated cell sorter (FACS) 
measures the florescence of each cell and separates a populations based on user defined 
criteria. This technique can be applied to the surfaces of mammalian, yeast, and bacterial 
cells (66).  After cells displaying protein that meets the user-defined criteria are selected, 
they are amplified and this process is repeated until the library is sufficiently enriched. 
This process is outlined in the figure below. 
 
 
Figure 1.16: The FACS sorting process outline for surface display (64) 
The advantage of this technology is that cells are much larger than phage and can 
be subjected to screening by fluorescence associated cell sorting (FACS). FACS combines 
high-throughput cell sorting with real-time quantitative analysis, allowing for library 
enrichment based on more than one criterion, such as antibody expression and affinity 
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(67). However, this technology is limited by the transformation efficiency of E. coli (thus 
limiting library size) and the sorting rate, both of which affect the ability for antibody 
screening. 
The surface display and selection process outlined in the figure above can be 
applied to select for different characteristics of many different protein types (68). One 
interesting example involves using FACS selection and surface display in order to engineer 
a protease with novel proteolytic activity for a peptide conjugated to a fluorescent probe 
(69, 70). In this example, the native peptide carried many charged amino acids but no net 
charge, while the cleaved peptide was highly positively charged and thus adhered to the 
negatively charged E. Coli membrane. Cells displaying highly proteases cleave more 
fluorescent peptide and thus these cells become brighter than cells with less active 
proteases. Rounds of FACS sorting that select for the most fluorescent cells enriched for 
protease variants with the desired specificity.  
When surface display is utilized for large antibody libraries, the antibody is 
anchored to the cell surface and the fluorescent probe is the antigen conjugated to a 
fluorescent molecule. Cells displaying antibodies that bind the antigen become fluorescent 
when they capture antigens conjugated to a florescent fluorophore; cells presenting 
antibodies with a stronger affinity for the fluorescent antigen capture more fluorescent 
molecules and thus become brighter than cells with weaker affinity. The FACS machine 
diverts the brighter cells in a separate collection tube order to create a population enriched 
for antigen binding activity.  
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FACS Technology 
Flow cytometry is a high throughput technique that analyzes the size and 
fluorescence of individual particles at a very high rate (>109 events/hr for the fastest 
machines) (71). Heterogeneous mixtures of cells in suspension are passed single file across 
multiple laser points. The light signals from the particles are registered and correlated to 
qualities such a cell morphology, protein expression, gene expression, and cellular 
physiology. The user can select cells with desired qualities and the machine will deflect 
these cells into a separate container. This separation happens exceptionally fast, is highly 
accurate, and is not destructive to the cell. The applications to biotechnology are vast and 
essential for many modern practices (71, 72).  
 
Figure 1.17: The essential process of the FACS machine (65). Cells in individual droplets 
are flown past multiple lasers (green and red) and their fluorescence is 
measured. Individual cells with a user-defined fluorescence are directed into a 
separate collection tube by the magnetic blocks (grey). 
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Bacterial Cell Antibody Surface Display 
The first E. coli based surface display methods were developed in the late 1980s; 
these early techniques fused foreign epitopes to the endogenous outer membrane proteins 
(73). In the early technologies, antibodies displayed on the surface are anchored to the 
endogenous outer membrane protein A (OmpA). Using this technology, successful 
enrichment of a library for a specific antibody was demonstrated using outer membrane 
protein expression (74). This system displays antibodies on the surface of the cell by fusing 
an antibody scFv to a hybrid of endogenous E. coli outer membrane proteins Lpp and 
OmpA.  
The utility of antibody surface display via the Lpp-OmpA system is limited to scFv 
format antibodies binding small molecule antigens. Successful studies demonstrating 
antibody binding to larger more complicated antigens have not been reported using this 
system in E. Coli; such complications are likely because the outer membrane of bacteria is 
full of LPS which carry a high negative charge that could restrict access for large globular 
protein antigens. Recently, other bacterial strains have been found to accommodate large 
protein-antibody interactions, but by the time these discoveries were published, the field 
had already evolved towards other solutions for bacterial surface display of antibodies 
(75).  
The first evolution of bacteria display technology away from the outer membrane 
problems associated with the Lpp-OmpA system was to move antibody production from 
the outer surface to the bacterial periplasm. The periplasm is the space between the inner 
and outer membranes. Periplasmic Expression with Cell Sorting (PECS) is an “anchor-
less” technology for discovering ligand-binding proteins where proteins are expressed in 
the periplasmic space then incubated the cells with fluorescently labeled ligand (76). 
Because the ligand-binding proteins are too large to diffuse through the outer membrane, 
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the cell acts as the link between genotype and phenotype. Usually only molecules smaller 
than 650Da can diffuse through the outer membrane of E. coli, however, this technology 
uses conditions such that up to 10kDa proteins can diffuse through the membrane. Cells 
expressing ligand-binding proteins in their periplasmic space bind and retain fluorescent 
ligand; the tighter the binding interaction the more ligand is retained in the periplasmic 
space and thus those cells become more fluorescent. Successive rounds of cell sorting for 
the brightest bacteria have been shown to enrich for ligand binding proteins. PECS has 
been employed to select for antibody scFvs that bind the small molecule digoxigenin 
conjugated to a 10kDa fluorophore (76).  
PECS does not allow for selection of large protein-protein interactions because the 
technology relies on the diffusion of one ligand through the outer membrane of the 
bacterium. This problem was solved by anchored periplasmic expression (APEx): an E. 
coli based display technology that links the ligand-binding protein to the periplasmic face 
of the inner membrane of the cell. APEx is a particularly important advance because it 
allows for selection of scFv antibodies that bind large proteins. Periplasmic anchoring 
allows for outer membrane permeablization without the scFv antibody diffusing away and 
thus terminating the link between genotype and phenotype (77). Once the outer membrane 
has been permebleized, large proteins (up to 240kDa) can diffuse into the periplasmic 
space where they can be retained by scFv antibodies. Cell sorting can then be used once 
again to sort a library of scFvs for antigen binding.  
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Figure 1.18: Method outline for the APEx system (77). After removal of the outer 
membrane and cell wall, cells are labeled with fluorescent antigen and sorted 
with a FACS machine in order to enrich for antigen binding cells.  
Permeablization of the outer membrane is also called spheroplasting. Under typical 
spheroplasting conditions, a cell is treated the following way: 
1. Cell pellets are resuspended in a hypertonic tris-sucrose solution  
2. Outer membrane is solubilized by EDTA, which chelates the magnesium 
ions stabilizing the cellular outer membrane  
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3. Lysozyme is added to break the cell wall down 
4. MgCl2 is added to quench the EDTA and stabilize the outer membrane 
The spheoplasting procedure kills the cells (lysozyme is commonly known as the 
antibacterial enzyme from hen egg white). Since the cells are not able to grow upon 
sorting, their genes are instead recovered by PCR, which generally increases the time 
between cell sorting cycles by at least one day.    
All of the bacterial cell surface display technologies discussed thus far use scFv 
antibody fragments instead of full length IgGs. Monovalent scFv and Fab fragments are 
commonly used because they’re relatively simple to express in E. coli, however they are 
not always ideal therapeutic formats because of their short serum half-life and low 
thermostability(78). Therefore, antibody scFvs isolated using phage display, surface 
display or other techniques are converted into the full-length IgG format for therapeutic 
efficacy testing. However, scFvs converted into full-length IgG format often show reduced 
or completely lost antigen-binding ability. Additionally, scFvs discovered using anchored 
display technologies, such as phage panning and APEx, are occasionally dependent on 
anchoring in order to fold correctly and bind antigen. E-clonal technology addresses these 
problems by producing full length IgG in the periplasmic space and “capturing” the full 
length IgGs via anchored ZZ protein, a protein A derivative that binds the Fc of IgG (67, 
79). Capture instead of anchoring is an valuable improvement because the ZZ protein will 
only recognize correctly assembled Fc fragments, ensuring selection of properly folded 
IgG. Selection of full length antibody IgGs removes the necessity for format conversion in 
order to pursue studies that further characterize the effectiveness of the antibody(80). The 
scheme has been successfully used to discover antibodies that bind the protective antigen 
of the pathogen Bacillus anthracis. The format for the E-clonal system outlined in the 
figure below. 
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Figure 1.19: a comparison of APEx technology (b) and E-Clonal technology (c) with 
reference full-length antibody (a). APEx technology displays scFv antibody 
fragments anchored to the inner membrane of bacteria while E-Clonal 
technology attaches full length antibodies to the inner membrane that are 
captured by an anchored protein A domain. (80) 
Yeast Display 
Yeast display was first described in 1997 as an alternative screening technology to 
bacterial display(81). This technology display a library of antibody scFvs fused to the C-
terminus of the yeast a-agglutinin on the surface of Saccharomyces cerevisae. An 
important feature of this technology is that it circumvents the unpredictable expression 
biases that occur when eukaryotic proteins are expressed in E. coli. Bacteria possess a 
limited ability to solubly express many disulfide bonded mammalian proteins, such as 
antibodies, because they lack the eukaryotic proteins that help chaperone and fold a 
protein. S. cerevisae have a surprisingly homologous folding and secretory machinery 
when compared to mammalian cells, therefore expressing mammalian cell proteins such as 
antibodies in S. cerevisae is an important improvement over bacterial expression. The ideal 
scenario for surface expression that would exclude any machinery biases and provide 
mammalian glycosylation profiles would be mammalian cell surface expression. These 
technologies have been developed, but slow culture times and inefficient cloning 
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techniques required to regulate expression levels and library size make these technologies 
limited in application (82, 83).  
 Display on the surface of S. cerevisae is accomplished by fusing the scFv to the 
two-subunit protein a-agglutinin. The Aga1p subunit anchors the protein fusion to the cell 
wall by β-glucan linkage; the subunit Aga2p is anchored to the Aga1p subunit through two 
disulfide bonds.  
 
Figure 1.20: Yeast display antibody selection platform as depicted in the original 1997 
paper from Dane Wittrup (81)  
This usefulness of this technology was originally demonstrated to by affinity 
maturation of an scFv. Studies have further validated the usefulness of this technology by 
discovering ligand binding by non-immunoglobulin proteins, discovering an antibody with 
48fM dissociation constant, and creating a non-immune human antibody library of over 109 
variants (84-87).  
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Cell Free Technologies: Ribosome display 
Ribosome display is an interesting and useful technology because it can select 
binders from a large library without using cells at any step(88). This is particularly 
important because the library size of cell based techniques is limited by the transformation 
efficiency of the cell (107-108 cells/ug DNA for yeast and 109-1010 cells/ug DNA for E. 
coli), while in vitro display technologies such as ribosome display can handle libraries with 
up to 1014 members(89). Another advantage of an entirely in vitro approach is that random 
mutations can be introduced after each round, as no library diversification step is required.  
Ribosome display creates a link between genotype and phenotype during an in vitro 
translation by stabilizing a complex comprising the ribosome, mRNA, and the folded 
antibody(90). In order to create this link, the library of antibodies is genetically fused to a 
spacer sequence without a stop codon. When the space sequence is translated it is still 
attached to the tRNA and occupies the ribosome, thus allowing for an attachment of the 
antibody to its mRNA. Selections are performed on the complex in a similar way to phage 
panning. The recovered fraction is then subjected to reverse transcription and PCR in order 
to amplify the DNA of the recovered fraction for another round of screening. This process 
is outlined in the figure below.   
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Figure 1.21: The principal of ribosome display (91).  
Ribosome display has proven a useful addition to the repertoire of technologies and 
techniques available for antibody discovery. This technology has been used to discover 
picomolar affinity antibody from a fully synthetic native library (91).  
Similar cell free display technologies have been utilized with similar results. For 
example, mRNA display technology achieves the covalent link between protein and 
mRNA through a puromycin adaptor (92). 
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Chapter 2 
 Antibody-Mediates Inhibition of Human C1S and the Classical 
Complement Pathway  
 
Regulating the complement system with antibodies has recently become a high 
profile drug discovery strategy following the FDA approval of the first complement 
specific drug, eculizumab, and its further investigation in 39 clinical trials registered with 
the US National Institute of Health (93). This work expands on the strategy of systemic 
regulation of complement (as is the case with eclulizumab) by instead inhibiting a specific 
arm of complement, the classical complement pathway. In order to inhibit that the classical 
complement pathway, an antibody was developed that modulates the signaling 
subcomponent of the pathway initiating C1 complex, C1s. This work includes novel 
protocols and strategies used for discovery and characterization of antibody D, which binds 
and inhibits C1s protease activity. Through numerous cell and plate based assays, antibody 
D is shown to regulate classical complement when the pathway is selectively activated by 
surface bound immunoglobulin. It is further shown that affinity maturation of antibody D 
results in higher levels of complement inhibition at various antibody concentrations. In 
summary, this work marks the first example of an antibody that specifically regulates the 
classical complement pathway by targeting the C1s protease on the pathway initiating C1-
complex.  
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INTRODUCTION 
The complement pathway is critical for the proper clearance of pathogens and 
apoptotic or damaged cells. The complement system comprises three semi-independent 
pathways: classical, alternative and lectin-mediated (20). The classical complement 
reaction cascade is initiated when the C1-complex, the only dedicated component of this 
pathway, binds to immune complexes or to C-reactive protein (CRP) deposited on 
apoptotic or damaged cells. The C1 complex is composed of one C1q molecule containing 
six terminal C1q globular heads, two C1r protease molecules and two C1s molecules.  
Binding of C1q to immune complexes formed by IgM or by certain IgG subclasses (IgG1, 
IgG2, IgG3) results in the activation of C1r which in turn cleaves and activates C1s.   
Subsequently, the active form of C1s specifically cleaves the serum complement proteins 
C2 and C4 (21) forming, respectively, C2b and C4b which associate into the C2bC4b 
complex that constitutes the C3 pro-convertase. The subsequent steps in the reaction 
pathway ultimately result in opsonization, release of anaphylaxins (C3a, C5a) and in the 
deposition of the membrane attack complex that forms holes on the membrane of the target 
cell thus mediating cell killing. 
Disregulation of classical complement activation is associated with numerous 
human diseases including rheumatoid arthritis, transplant rejection, ischemic reperfusion 
injury (94, 95) and neurological disorders (96).  Therefore, pharmacological inhibition of 
complement is highly desirable and the subject of intensive research (97, 98).   Eculizumab 
(trade name Soliris), which inhibits the processing of C5 and formation of the 
anaphylatoxin C5a, interferes with a reaction that is common to all three complement 
reaction cascades and has been approved for the treatment of the orphan disease, 
paroxysmal nocturnal hemoglobinuria (93). So far only one upstream inhibitor of the 
classical pathway, human plasma-derived C1 inhibitor (C1-inh, trade names CINRYZE 
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and Berinert for the blood isolated protein and Rhucin for the recombinant C1-inh) has 
been approved for treatment of hereditary angioedema (99) a disease caused by a genetic 
defect in endogenous C1 inh. C1-inh is a serpin with broad substrate specificity that 
irreversibly inactivates several serum proteases including C1r, C1s, MASP-1, MASP-2, 
thrombin and other enzymes of the fibrinolytic, clotting and kinin pathways 
(100).However, high doses of C1-inh are associated with increased incidence of 
thrombotic events (http://www.fda.gov).  Further, supra-physiological levels of C1-inh 
downregulate all pathways of complement activation (101) and therefore they can 
negatively impact the beneficial effects of complement in pathogen and malignant cell 
elimination.  It is of note that at over $300,000 per year per patient, both Eculizumab and 
CINRYZE are the two highest priced approved drugs (102).   
Inhibitors of the classical pathway displaying improved selectivity relative to 
CINRYZE are highly desirable. Such high selectivity can be achieved using antibodies.  In 
earlier studies, antibody fragments that block the globular heads of C1q and thus prevented 
the binding of immunoglobulins or CRP were reported (103, 104). However, when C1q-
specific antibody fragments are present in an IgG, which is therapeutically more relevant 
because of its much longer serum persistence, the bivalency of the molecule results in 
complement activation instead of inhibition.   
In this work we describe the engineering of human antibodies that inhibit the 
catalytic activity of C1s. Phage display of a very large synthetic library resulted in the 
isolation of an FAB, (clone D), that bound to C1s with nanomolar affinity and an even 
higher apparent affinity when formatted as an IgG molecule, due to avidity effects.  
Further, affinity maturation of the scfv D resulted in a variant, D.35 with sub-nanomolar 
monovalent affinity.  Importantly, D and D.35 were shown to inhibit C2 and C4 processing 
in serum and complement deposition and lysis of antibody-sensitized cells. However, 
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unlike C1-inh, they did not bind to other serum proteases. These findings suggest that C1s 
inhibitory antibodies may be of interest for the inhibition of the classical complement 
pathway in disease settings. 
 
RESULTS 
Antibody Isolation and Affinity Maturation 
Our initial efforts to generate inhibitory antibodies to human C1s, either from 
animal immunization and V gene repertoire analysis (105) or by panning of scFv libraries 
from immunized animals led to the isolation of several clones which bound with high 
affinity (e.g. Reddy et al. 2010) but failed to inhibit the formation of C2b by activated C1s. 
Similarly, phage panning of a very large human synthetic (FAB)2 library constructed by 
Sidhu and coworkers (106) resulted in the isolation of two antibodies (clones A and B)  
which displayed subnanomolar apparent affinity according to ELISAs (Table 2.2)  
however also failed to inhibit the cleavage of C2 in vitro  (data not shown). C1s comprises, 
starting from the N-terminus, a CUB module (107), an epidermal growth factor (EGF)-like 
module, a second CUB domain, two complement control protein domains (CCP) and a C-
terminal chymotrypsin-like serine protease (SP) domain (23). We reasoned that only 
antibodies to SP are likely to be inhibitory and that the use of intact C1s as the immunogen 
may be resulting in the generation of antibodies to one or more of the N-terminal, non-
catalytic domains. To test this hypothesis, a truncated form of C1s lacking the two CUB 
domains as well as the EGF-like domain and comprising only of the two complement 
control domains and the protease active site  (CCP2-SP) was expressed in insect cells and 
purified to near homogeneity  (Figure 2.14). We found that, as had been expected, 
antibodies A and B failed to bind to CCP2-SP and therefore must recognize the N-terminus 
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of C1s. To isolate antibodies with inhibitory function, the synthetic library was subjected 
to two rounds of panning against activated CCP2-SP followed by additional panning with 
full length protein in order to ensure that clones specific to the catalytic domain can also 
bind to it in the context of the intact protein (Figure 2.1). After a total of 5 rounds of 
panning, five distinct clones (Tables 2.1, Sequences C-G) were isolated of which 4 were 
specific for CCP2-SP (Figure 2.2).  
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Figure 2.1: Phage panning overview used for discovery of antibodies reactive against the 
complement C1s serine protease. A human synthetic antibody phage library 
was enriched for binding to the C1s active domain (second CCP domain and 
serine protease domain: CCP2-SP) by three rounds of panning against the 
CCP2-SP antigen.  A further three rounds of panning was performed against 
the entire C1s protease. Library is further described in Materials and 
Methods.  
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Table 2.1: Antibody Heavy and Light Chain Sequences. This table reports the heavy chain sequences of the variable region of 
each of the reported antibodies with color used to highlight differences.  
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Antibody Kd CDRH3 length 
A 20pM 14 
B 20pM 13 
C 130pM 10 
D 2nM 18 
E 4nM 13 
F 90nM 19 
G 35nM 22 
Table 2.2 Antibody Properties. Affinity and CDR-H3 length as determined by ELISA 
and IMGT/V-QUEST respectively 
 
 
Figure 2.2: Evaluation of phage binding to C1s.  CCP2-SP, C1s, or milk were coated as 
capture antigens (400 nM) for ELISA testing of phage binding specificity as 
described in Materials and Methods.  Antibodies A-B (left of bar) were 
isolated from panning against C1s antigen only, whereas C-G were isolated 
with the scheme depicted in Figure 2.1. Nearly all antibodies isolated using 
this scheme were reactive with both the CCP2-SP truncated antigen and the 
full length C1s protein.  
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Antibody fragments were expressed as monomeric FABs and were tested for 
inhibition of the proteolytic activity of activated C1s was determined using a FRET 
peptide substrate (108). One FAB, (antibody D) exhibited significant inhibition in this 
assay and was characterized further (Figure 2.3).  
 
Figure 2.3: Fluorescence resonance energy transfer (FRET) peptide proteolysis assay.  
Relative activity of C1s in the presence of an excess of antibody. Activity 
was measured by comparing signal from cleaved FRET substrate in the 
presence of excess antibody compared to no antibody control.  Among the 
several isolates (antibodies C-G), Antibody D displayed the greatest 
inhibition of C1s protease activity.  Measurements were made in triplicate.  
Error bars depict standard deviation.  
 
Antibody D contained an 18 aa long VH CDR3 significantly longer than the mean 
CDR3 length for mice or humans (12 aa Human, 9 aa mouse (109)). The equilibrium 
dissociation constant to C1s was determined by kinetic equilibrium exclusion analysis 
using a KinExa instrument and was found to be 1.7 nM (95% confidence 1.1-2.2nM) in 
close agreement with the value determined by competition ELISA. Expression of this 
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antibody as a full length human IgG in HEK293T cells resulted in more potent inhibition 
of C2 by SDS-PAGE as expected from the higher avidity of the bivalent antibody format 
(Figure 2.4) 
 
 
 
Figure 2.4: C2 inhibition assay with IgG and fAb format antibody D. Ratios of inhibitor 
antibody to C1s are shown above bands. Accumulation of proteolysis 
products from the C1s substrates C2 were detected by SDS-PAGE and 
indicated by the arrows drawn. Reactions were run in the presence of 
different molar ratios of Fab or IgG antibody to C1s (indicated above each 
column).   
 
To improve the equilibrium binding affinity of antibody D for C1s, first it was 
expressed as scAb (a scFv fused to a human Ck which improves expression in E.coli). 
Purified D scAb was shown to display a binding affinity identical to that of the FAB 
ELISA (Figure 2.5).  
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Figure 2.5: Affinity of D in various formats. Serial ELISA dilutions were performed 
using antibody D in scAb and fAb format. Dissociation constants were 
estimated by ELISA to be identical.  
 
Then the corresponding scFv domain was subcloned into plasmid pAPEx1 for 
anchoring on the inner membrane of E.coli to enable flow cytometric screening by the 
anchored periplasmic display (APEx methodology, Figure 2.6). Following random 
mutagenesis by error prone PCR, a library of >107 transformants was subjected to 3 
rounds of screening fluorescently labeled C1s at 20nM.  Three rounds of screening 
resulted in a 3.5-fold increase in the mean cell fluorescence. 10 clones from the third 
round were grown individually and the scFv from one clone, D.35 displaying the highest 
fluorescence was expressed in soluble form (Figure 2.7). KinExa analysis indicated that 
the D.35 scFv displays a KD= 0.95nM (95% confidence interval (1.1-0.76nM Table 2.3) a 
2-fold improvement relative to the parental scFv (Table 2.3).   
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Figure 2.6: Anchored periplasmic expression (APEx) schematic for affinity maturation 
of anti-C1s antibodies. Mutagenic libraries of the parental anti-C1s antibody 
(hereafter referred to as Antibody D) were expressed as anchored scFvs on 
the inner membrane of E. coli. Bacteria were spheroplasted and incubated 
with fluorescent antigen before being subjected to FACS sorting. After 
multiple rounds of screening the highest affinity clones were selected for 
further analysis.   
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Figure 2.7: Fluorescence activated cell sorting (FACS) to select high-affinity variants of 
the D anti-C1s antibody. FACS signals of individual clones were compared 
by mean fluorescence intensity (MFI): FACS signals of negative control 
antibody M18 (blue), wild-type antibody D (red) and affinity matured 
antibody D.35 (green).  
 
 KD 95% High 95% low 
D 1.7 2.2 1.3 
D.35 0.95 1.1 0.76 
Table 2.3: KinExa Analysis of Antibodies. Affinity of D and D.35 as determined by 
KinExA. 95% confidence intervals are also reported. 
 
The light chain mutation S56P is the D.35 mutation (Table 2.1). Further attempts 
at affinity maturation though random mutagenesis failed to give any further KD 
improvement in contrast to other studies that generated 35-270-fold improvements using 
similar techniques (77, 110, 111). Attempts at affinity maturation through phage panning 
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a library with diversified light chain CDRs constructed as described by Ge et al. were 
also unsuccessful (112). The inability to further affinity mature antibody D may be a 
consequence of the antibody-antigen interface created exclusively by the long (18 aa) 
CDRH3 loop. If this is indeed the case, future mutagenesis should focus on exclusively 
on CDRH3.   
The affinity-enhanced antibody (D.35) was then investigated for increased C1s 
inhibition by direct detection of C1s mediated proteolysis substrates C2 and C4. C1s, 
antibody, and substrate were incubated for 50 minutes at different antibody/C1s ratios 
and immediately ran on an SDS-PAGE gel.  D.35 was determined to better inhibit C1s 
activity by inspection of the intensity of the commassie bands from the proteolysis 
products (Figure 2.8).  
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Figure 2.8: Antibody-mediated inhibition of C1s proteolytic activity.  Accumulation of 
proteolysis products from the C1s substrates C2 and C4 were detected by 
SDS-PAGE and indicated by the arrows drawn. Reactions were run in the 
presence of different molar ratios of FAB antibody to C1s (indicated above 
each column).   
 
Inhibition of the classical complement activation pathway  
Ramos is an EBV-negative, lymphoblastoid cell line derived from a B cell 
lymphoma that expresses high levels of the B cell surface marker CD20 (113).   The anti-
CD20 therapeutic antibody rituximab mediates the ablation of CD20 expressing cells to a 
large part via the activation of complement on target cells (114) and is used for the 
treatment of lymphomas and in autoimmunity. The ability of the D and D.35 FABs to 
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inhibit the activation of the classical complement pathway was evaluated by monitoring 
the deposition of the C3b convertase on the surface of antibody-sensitized target cells. 
Activation of C2 and C4 by C1s results in the formation of the C2bC4b complex, or C3 
convertase, which promotes cleavage of the very abundant protein C3 into C3a and C3b. 
The latter is deposited on the cell surface where, together with C2bC4b forms the C5 
convertase. The deposition of C3b on the surface of rituximab-sensitized cells in the 
presence or absence of inhibitors was determined by flow cytometry using a fluorescently 
labeled anti-C3b antibody in the presence of 40% of fresh human serum. The presence of 
9uM C1 inh reduced C3b deposition detected by FACS signal approximately 25 %.   The 
same level of inhibition of complement activation was observed with FAB D while the 
affinity matured variant D.35 conferred approximately 2-fold greater inhibition resulting 
in approximately 46% reduction in C3b deposition relative to control cells incubated 
without inhibitor.   
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Figure 2.9: FACS detection of surface bound complement component C3b on rituximab 
sensitized Ramos cells in the presence of selected inhibitors. C3b is a 
complement protein near the middle of the complement cascade that binds 
surfaces undergoing complement attack. C3b levels were detected with 
fluorescent antibody after cells Ramos were incubated with 25uM inhibitor 
and 33% Normal Human Serum (NHS). 
 
IgM is a potent activator of the classical complement pathway, and activation of 
the classical complement biochemical cascade occurs when C1 complex binds a single 
surface bound IgM molecule. The deposition of late complement component C5-9b was 
detected on IgM coated ELISA plates in the presence of 35% serum. Several dilutions of 
each inhibitor from 9.2uM to 1.8uM were incubated in 35% serum for 50 minutes. At 
9.2uM, the maximum concentration of each inhibitor, D.35 and D exhibited 43% ±	  6%	  
and 56% ±	  6%	  of the C5-9b signal from uninhibited serum deposition while 81% ± 1% 
C5-9b signal was detected on cell in the presence of exogenous C1-inh (figure 2.10).  
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Figure 2.10: Inhibition of complement protein C5-9b deposition onto IgM coated ELISA 
plates. C5-b9 is a late complement protein deposited onto surfaces 
undergoing attack by complement. C5-b9 was detected with a C5-9b 
specific antibody conjugate after complement was activated in the presence 
of various concentrations of inhibitors between 9.2-1.8uM. OD405 values for 
wells were divided by uninhibited activated complement to give relative 
levels.  
Finally, to monitor the inhibition of complement mediated lysis of Ramos cells 
sensitized with rituximab, we monitored the release of calcein.  Cells were incubated with 
calcein-AM which readily diffuses into cells where active cellular esterases cleave the 
acetomethoxy group to generate highly florescent calcein that can no longer diffuse 
through cellular membranes.  Thus the fluorescence in the culture supernatant is 
indicative of the extent of cell lysis. Cells were sensitized with 0.1ug/ml rituximab in 
40% fresh human serum with several dilutions of each inhibitor from 9.2uM to 1.8uM for 
25 minutes at which point the supernatant was collected and the fluorescence was 
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monitored. At the maximum concentration of each inhibitor, D.35 and D exhibited -3% ±	  21%	   and 15% ±	   9%	   of the calcein released from uninhibited serum deposition while 
62% ± 5% calcein release was detected on cell in the presence of exogenous C1-inh 
(figure 2.11).  
 
 
Figure 2.11: Lysis of Ramos cells in the presence of rituximab and selected inhibitors. 
Cell lysis by complement occurs when pores are formed on the cell surface 
by terminal membrane attack complexes. Cell lysis was measured by the 
complement-mediated release of fluorescent calcein in the presence of 
inhibitor concentrations between 9.2 and 1.8uM. Relative values were 
calculated by dividing the specific release of wells with inhibitor by the 
specific release from uninhibited wells.  
Together these three assays demonstrate that an antibody that binds and inhibits 
the C1s protease on the C1 complex can regulate classical complement activity. 
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Furthermore, affinity maturation of Antibody D to D.35 improved classical complement 
regulation compared to the wild type Antibody D.   
 
The Specificity of Antibody D 
Specificity is an important aspect of any antibody. Many monoclonal antibodies 
fail to be therapeutically useful because they bind both the intended protein and an 
unintended homologous protein, resulting in unintended consequences. Because C1s is 
homologous to many proteins, including the other constitutive protease of the C1 
complex, C1r, it is important to determine the specificity of D for its intended target C1s.  
A capture ELISA was run in which C1s, C1r, or unactivated proenzyme C1s 
(pC1s) was adsorbed to the plates. Serial dilutions of antibody FAB D were incubated with 
the adsorbed antigen followed by detection with anti-Flag-HRP. The results indicate that 
FAB D is highly specific to C1s, the was no observed binding to homologous protein C1r 
and the affinity for pC1s was observed to be ten-fold less than the C1s signal.  
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Figure 2.12: Antigen specificity of D. Serial ELISA dilutions were performed by incubating 
antibody D against different immobilized antigens. The specificity of D to the 
active form of C1s is indicated by the higher ELISA signal and lower antibody 
concentrations. Antibody D has no detectable binding to C1r. EC50 of FAB D is 
estimated to be ~1nM for C1s and ~20nM for proenzyme C1s. 
 
 
Discussion 
Abnormal classical complement activation contributes to the pathogenesis of 
many diseases such as rheumatoid arthritis, transplant rejection, and even neurological 
disorders such as Alzheimer’s disease (94-96); therefore therapeutic regulation of 
classical complement is a highly desirable goal. In this work, we developed an antibody 
that inhibits the signaling protease of the pathway-initiating C1 complex, C1s. Specificity 
is an extremely important quality of a potential therapeutic inhibitor, and poor specificity 
is often the reason many protease inhibitors are not very effective (115). In earlier 
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studies, C1s was targeted by a small peptidomimetic molecule and was shown to be 
effective in reducing classical complement activation in rabbits (116). However the short 
half life and low specificity of this molecule have prevented its further development as a 
drug candidate (97). In contrast human antibodies are ideal therapeutic molecules because 
of their high specificity, long half-live in circulation and low immunogenicity (117).  In 
this work, phage display using a large diversity library was used to isolate antibody D, 
which binds activated C1s with nanomolar affinity and inhibits its proteolytic activity.   
Antibody D preferentially binds the active C1s molecule compared to the 
inactivate form and exhibits 20 fold lower EC50 for active C1s than the proenzyme form 
(Supplemental figure 3a).  It contains an unusually long CDR3 (18 aa) which may be 
important for binding to the active site cleft of C1s.  Long CDR3s have been observed in 
several antibodies selected for their ability to inhibit hydrolytic enzymes (115, 118). 
A variety of approaches were employed in an effort to isolate affinity improved 
variants of the D antibody fragment from libraries generated by either random 
mutagenesis or by DNA shuffling (112, 119) and screened by phage display in solution 
or alternatively by APEx.  A variant displaying a modest 2-fold higher affinity could only 
be isolated by using three rounds of APEx; further mutagenesis and screening failed to 
yield any clones displaying further improvement in the equilibrium dissociation constant 
to C1s.  This is in contrast to other studies from our lab and others where affinity 
improvements from the nM range to 10s of pM could be obtained by surface display for a 
variety of antibodies (77, 110, 111). The difficult in achieving a significant enhancement 
in the affinity of antibody D may be due to its unusually long CDR3. In this case, further 
affinity improvements may need introducing mutations within the CDRH3 loop in order 
further optimize the contact interface.  
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The FAB D and its affinity improved variants D.35 FAB were shown to inhibit the 
deposition of C3b on CD20 expressing cells sensitized with the anti-CD20 antibody 
rituximab and also the formation or the C5-9b complex at 9.2uM in 35% serum. 
Importantly, the D.35 FAB was shown to protect CD20 expressing cells from complement-
mediated lysis more effectively than the clinically used complement inhibitor C1-inh in 
the presence of 40% serum.   
The C1 complex is a very attractive target for selective inhibition of the classical 
complement pathway because it is the only member of the classical pathway that does not 
participate in the other complement pathways. There are two possible strategies for 
blocking the activation of the C1 complex: (1) preventing the C1q heads from 
recognizing substrate and (2) blocking signaling upon complex activation by targeting the 
C1s protease. Inhibition of C1s rather than C1q offers several advantages: (1) there are 
three times fewer C1s molecules relative to C1q globular heads. (2) Because the inactive 
C1s zymogen is structurally different than the active C1s, it is possible to generate 
inhibitors that block only activated C1 complex  (3) Inhibition of C1q by full length 
antibodies is undesirable because the avidity effect of bivalent IgG can actually induce 
C1q activation (103) . Full length IgG molecules are much more desirable as therapeutics 
because of their higher apparent affinity relative to monovalent antibody fragments 
(nearly 10-fold) (120) and their significantly increased serum half-life due to  the 
interaction of the Fc region of the antibody with the neonatal Fc receptor (17).  
Complement regulation is made difficult by high serum concentration of its 
constitutive proteins, requiring high concentrations of inhibitors to counteract them. C1 
complex is normally found at 240nM in serum, therefore C1s and C1q are found at nearly 
480nM and 1.440uM respectively (121). In this study, complement mediated lysis of 
RAMOS cells was greatly reduced when 9.2uM of antibody D.35 was used in 40% 
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serum, which implies that 23uM of antibody would be required for similar effectiveness 
in potential patients (100% serum). Therefore, further improvement of the antibody D.35 
is required to in order to achieve effectiveness at therapeutically relevant concentrations 
(<1uM). Potential methods for improvement could come from continued affinity 
maturation or through bivalency, which generally results in a 10-fold apparent affinity 
improvement (120). 
In order to address the exceedingly high concentration of FAB D.35 inhibitor 
required for complement inhibition, a combination of antibody inhibitors might be a 
desirable approach to limit complement activation at lower antibody concentrations. It is 
therefore particularly relevant that we have shown novel methodologies for discovering 
and affinity maturing such antibodies that can be easily tailored to different classical 
complement proteins or an entirely different pathway. Alternative antibody-based 
classical complement inhibition strategies that prevent C1 complex signaling could be 
developed by slightly modifying our discovery scheme for development of antibodies 
that bind the proenzyme form of C1s or C1r.  
 
 
MATERIALS AND METHODS 
 
Insect Cell Expression and Activation of C1s active domain 
The active domain of C1s (second CCP domain and the serine protease domain, 
CCP2-SP, aa 358-688) was expressed with an N terminal 6X-His tag in Sf9 insect cells 
grown in Insect-XPRESS media (Lonza, 12-132A) with 5% FBS and 1x Penicillin-
Streptomycin (Invitrogen, 15070-063) essentially as described earlier (122). After 6 days 
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of cell culture 500mL of supernatant was aspirated and dialyzed using SnakeSkin dialysis 
tubing (10kDa MWCO Thermo, product #68100) 2X for 12hrs in 4L PBS, pH 7.5.  
Inactive CCP2-SP was purified from dialyzed supernatant by Ni-NTA 
chromatography.  Briefly, 25mM imidazole was added to 500mL of dialyzed supernatant 
then passed three times over 1ml of Ni-NTA slurry (Qiagen, 30250) in a polypropylene 
column (Thermo, 29922). The column was washed by passing 10ml of PBS, pH 7.5, 
25mM imidazole before eluting twice with 0.5ml of PBS, pH 7.5, 250mM imidazole. 1ml 
of eluent was collected and dialyzed into 500 ml PBS, pH 7.5 with a Slide-A-Lyzer 
dialysis kit (Thermo, #66003). Purified inactive CCP2-SP was quantified by measuring 
absorption at A280 in a NanoDrop instrument and adjusted to 6uM in PBS, pH 7.5 (ext 
coefficient 66975 M-1cm-1 (calculated via http://web.expasy.org/protparam/) protein M.W. 
39kDa).  
 
Figure 2.13: Visual comparison of the domain structure of CCP2-SP vs C1s. Domain 
structure of CCP2 from left (N terminal) to right: CCP2, SP. Domain 
structure of C1s from left (N terminal) to right: CUB1, EGF, CUB2, CCP1, 
CCP2, SP. Glycosylation sites are found on the EGF domain and the CCP2 
domain.  
Activated CCP2-SP was generated by incubating 6 uM CCP2-SP with 0.2uM C1r 
(Complement Tech, #A102) in PBS, pH 7.5 at 37°C for 2 hours. Activated CCP2-SP was 
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then adjusted to 20% glycerol and stored at -80°C until needed. Activation of CCP2-SP 
was confirmed by monitoring C2 proteolysis as follows: 1ul of 6uM activated CCP2-SP 
was incubated with 3 ug of C2 (ComplementTech, A112) in 10ul PBS, pH 7.5 at 37°C 
for 30 min.  The activated CCP2-SP and C2 solution was then boiled in 1X non-reducing 
SDS-PAGE buffer (Invitrogen, LC2677) and analyzed by SDS-PAGE (NuSep, NG21-
420) (Figure 2.14).  
 
Figure 2.14: Insect cell expression of C1s active domain (CCP2-SP). Lanes 1-4 : (1) 
Inactive CCP2-SP, (2) activated CCP2-SP, (3) C2 incubated with unactivated 
CCP2-SP, (4) C2 incubated with activated CCP2-SP.  
Phage Panning  
The human synthetic (FAB)2 phage library F constructed on the phagemid FAB-C 
(106) was generously supplied by Sachdev Sidhu (59). 
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Table 2.4: The sequence diversity allowed for LibF 
Before panning, 3 ml activated CCP2-SP or full length active C1s 
(ComplementTech, A103) at 4 ug/ml in PBS, pH 7.5 was adsorbed onto immunotubes 
(Nunc #444202) overnight by rotating at 4°C. Coated tubes were then blocked with PBS, 
pH 7.5 containing 2% milk for 2 hours at room temperature. Coated and blocked tubes 
were then incubated with 3 ml of PBS, pH 7.5, 2% milk with 1013 freshly purified phage 
at 25°C for 2 hours. Following incubation with phage, the immunotubes were washed 
20X with PBS, pH 7.5, 00.05% Tween-20. Phage bound to the immunotubes after 
washing were eluted by incubation with 1mL of 100mM triethylamine (TEA) for 8 
minutes followed by neutralization with 1ml of 1M Tris-base, pH 8.0. Recovered phages 
in elution-neutralization buffer were then used to infect 10mL of E. coli XL1-Blue cells 
at OD600 0.3 for 1 hour in 2XYT media at 37°C.  Infected cells were recovered by plating 
on 2XYT +200 ug/ml carbenicillin plates and the plates were incubated overnight at 
37°C. Colonies recovered from plates were scraped and to prepare phage for the next 
round of panning according the standard protocol outlined by Fellouse and Sidhu (59). 
The first three rounds of panning were performed using immunotubes with activated 
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CCP2-SP adsorbed to the surface followed by three rounds panning using immunotubes 
with full length C1s adsorbed to the surface.  
After six rounds of panning, individual clones were evaluated by monoclonal 
phage ELISA. Colonies recovered from the final round of panning were grown in 150 ul 
2XYT media with 200 ug/ml carbenicillin in 96-well culture plates (Cellstar 650 180) by 
shaking overnight at 37°C.  2 ul of overnight cultures were subcultured into 170 ul media 
and grown for another 90 minutes in the same media at 37°C. Cultures were then infected 
with M13K07 helper phage (NEB, #N0315S) by adding 10 ul of 5x1011 phage-per-ml and 
incubating without shaking at 37°C for 1.5 hours. 2 ul of 5 mg/ml kanamycin was added 
to infected cultures followed by overnight shaking at 37°C. Overnight infected cultures 
were centrifuged at 3500 x g for 10 min then the supernatant was collected by pipette. 
100ul of supernatant was mixed with 100ul of PBS, pH7.5, 2% milk then 50ul of the 
solution was added to high binding ELISA plates (Costar 3590). ELISA plates were 
previously incubated with either 4ug/ml C1s or BSA control antigen and blocked with 
PBS, pH7.5, 2% milk.  After incubation with supernatant-PBS milk mixture for 1 hour at 
25°C, ELISA plates were washed 3X with PBS, pH 7.5, 0.2% Tween-20. Following 
washing, wells with bound phage were incubated with 50 ul of 1:5,000 anti-M13-HRP 
(GE 27-9421-01) in PBS, pH7.5, 2% milk for 30 minutes at 25°C. Plates were washed 
three more times, then bound phage was detected by adding 50ul Ultra TMB (Thermo, 
34028) to the plates and incubating for 15 minutes. Following incubation with TMB, 
plates were quenched with 50ul of 1M H2SO4. Absorbance at 450nm was measured using 
a 96-well plate reader and positive clones were determined by 5-fold higher 450nM 
signal on antigen-coated plates compared to BSA-coated plates.  
In order to enable soluble expression of FAB antibodies, phagemids from positive 
clones were modified with mutagenic primers such that a 10X poly-His tag followed by 
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two stop codons was inserted between the CH1 heavy chain constant domain and the 
gene3 fusion. Soluble FAB antibodies were generated from the mutated phagemid by 
overnight culture in 500 mL 2XYT at 37°C with 200uhg/ml carbenicillin followed by 
osmotic shock and Ni-NTA purification essentially as described (123).  
 
Antibody ELISAs 
ELISAs were performed in order to detect binding and estimate the EC50 values of 
FAB or scFv antibody fragments binding to antigen. 50 ul of 4ug/ml antigen in PBS, pH 
7.5 were adsorbed to 96 well high binding ELISA plates (Costar #3590) by incubating at 
4°C overnight. Plates were blocked by incubating with 250 ul PBS, pH 7.5, 2% milk at 
25°C for 2 hours. Serial dilutions of antibodies in PBS, pH 7.5, 2% milk were added to 
the plates in duplicate in order to cover a wide range of antibody concentrations then 
incubated on the plate for 1 hour at 25°C with mild shaking.  After washing 3X with 
PBS, pH 7.5 0.2% Tween-20, plates were incubated with 1:5,000 anti-EC5 HRP (Bethyl 
Labs, #A190-102P) for 30 min at 25°C with mild shaking. Plates were washed three 
additional times then bound antibody fragments were detected by adding 50 ul Ultra 
TMB (Thermo, 34028) to the plates and incubation for 15 minutes. The TMB solution 
was quenched with 50ul of 1M H2SO4 and absorbance was measured at 450nm using a 
96-well plate reader. EC50 values were estimated to be the 450 nm reading corresponding 
to half the maximum 450nm absorbance detected at saturating concentration of antibody 
fragment.  
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Affinity Maturation of antibody D  
The variable heavy and light chains of antibody D were subcloned into the scFv 
format with the light chain at the N terminus followed by a (Gly4Ser)4 linker and the 
heavy chain. Soluble expression of antibody fragments and ELISA assays to measure 
EC50s towardsC1s were performed essentially as described above. The dissociation 
constant of scFv format antibody D was estimated to be the same as the FAB format 
antibody. The scFv gene of antibody D was then subjected to random mutagenesis by 
error prone PCR (119). Following ligation into pAPEx1 (77) and transformation into 
E.coli Jude-1 cells (67), >107 transformants were obtained on selective plates. 
Sequencing of 10 randomly selected clones revealed a mutation rate of ~2.5 nucleotide 
substitutions per gene (0.3% bp nucleotide error rate).  Overnight cultures of 
transformants were induced by 1/100 subculture into terrific broth (TB) (BD, #243810) 
with 2% glucose and 1mM IPTG (EMD Millipore, #420322) for 4 hours and 37°C. 
Induced cultures were spheroplasted and incubated with 1/2000 anti-flag PE (Prozyme 
PJ315) and 20nM of C1s conjugated to Alexa Fluor647 (Invitrogen #A-20173) then 
subjected to three rounds of APEx sorting using a BD FACS Aria as previously described 
(111).  
Individual clones encoding scFv genes isolated from the third round of sorting 
were grown as above; the cells were, spheroplasted, and analyzed for expression and 
antigen binding via FACS. Clones exhibiting a higher Alexa Flour647 signal (indicative 
of improved binding to C1s conjugated Alexa Fluor 647) were selected for further 
analysis via ELISA and KinExA.  
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Determination of Dissociation Constant via KinExA  
Kinetic exclusion assays were performed with a KinExA 3200 instrument. C1s 
was adsorbed onto Poly(methyl methacrylate) (PMMA) particles (Sapidyne #440176) by 
mixing 1 vial of particles with 10ug of C1s in 1ml of PBS, pH 7.5 and rotating for 2 hr at 
room temperature. Beads were then blocked by incubation with 10mg/ml BSA and 
rotated for another 2 hours at room temperature.  A range of C1s concentrations from 500 
nM to 0.03 nM were incubated in PBS, pH 7.5, 1mg/ml BSA, 0.02% sodium azide with 
FAB antibody at either 1 nM or 0.1 nM for 24 hours at room temperature.  The solution 
was then applied to the beads using the KinExA 3200 autosampler followed by detection 
of free antibody was detected using 0.5ug/ml anti-human IgG Dylite 649 (Jackson 
Immuno #109-495-088). Data were collected in duplicate and equilibrium dissociation 
constants were determined using the KinExA n-Curve analysis software.  
 
C1s activity inhibition assays 
Purified soluble FAB proteins expressed from pFAB-S (pMAZ360-IgG vector with 
10XHis-2Xstop introduced between CH1 and CH2) were incubated in triplicate at 
500nM with 35nM C1s and 1uM synthetic C1s FRET peptide substrate (Anaspec 61318) 
at 37°C with shaking in flat bottom optical 96 well plates (Thermo Fisher 265301).  After 
10 minutes, the fluorescence intensity was determined using an excitation wavelength of 
320 nm and an emission wavelength of 420 nm. Relative C1s activity was calculated by 
dividing the emission value from test wells by the emission value from wells without 
antibody (only C1s and substrate). Antibodies exhibiting inhibition of C1s generated 
relative C1s values less than 1.   
The inhibition of C2 or C4 (ComplementTech A112, A105c) processing by 
activated C1s was determined by SDS-PAGE as follows: 10nM active C1s 
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(ComplementTech, A103) was preincubated with various stoichiometric ratios of FAB in 
PBS, pH 7.5 at 25°C for 5 minutes. Subsequently, either 2.5ug of purified C2 or 8ug of 
C4 were added then incubated for an additional 2 hours at 37°C.  Following incubation, 
samples were boiled for 5 minutes in 3x-SDS-PAGE buffer; proteins were resolved on a 
4-20% acrylamide gel (NuSep, #NG21-420) following the manufacturer’s instructions. 
Gels were then stained with gel-code blue (Thermo Scientific #24592). 
 
Treatment of Human Serum  
Blood (~15ml) was collected from human volunteers under IRB protocol 
#IRB000007066 approved by the Scott & White Hospital and by the University of Texas 
at Austin IRB committees. The blood was allowed to clot for 30 minutes at room 
temperature, the centrifuged for 10 min at 1000 x g, and the supernatant (serum) was 
collected into fresh vials. Sera were combined from 5 volunteers at a time and stored until 
use at 4 °C but for no more than one week.  
 
Complement Deposition and C5-b9 detection on IgM coated plates 
To monitor C5b-9 deposition, high binding ELISA plates (Corning, 3590) were 
prepared by adsorbing 50ul of 10ug/ml purified human IgM (Jackson ImmunoResearch, 
009-000-012) in PBS, pH7.5 at 4°C overnight then blocking with 250ul PBS, pH 7.5, 
.05% gelatin for 2 hours at room temperature. Samples were prepared by diluting 200ul 
of fresh human serum with 80ul of FAB, C1-inh (ComplementTech, A140) or PBS control 
in Dulbecco’s PBS (dPBS), pH 7.5 (Thermo, SH30028.02) and 280ul gelatin veronal 
buffer (GVB++, Complement Tech, B102). 50ul of each sample was added in triplicate 
to plates then incubated for 50 min at 37°C with mild shaking. Plates were washed 3X 
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with wash solution included in the COMPL CP 310 kit (Euro-Diagnostica) followed by 
incubation with 50ul of alkaline phosphatase labeled antibody (also included in COMPL 
CP 310 kit). An additional 3X washes were performed with included wash buffer, then 
C5-b9 was detected according to manufacturers instructions (Euro-Diagnostica, COMPL 
CP 310).   
Relative percent of classical complement mediated C5-b9 deposition was 
determined by dividing the absorbance at 405nm from test wells by the absorbance from 
wells with serum without inhibitor.  
 
Complement deposition and lysis of Rituximab sensitized cells.  
C3b deposition on Ramos cells, a Burkit cell lymphoma line, sensitized with the 
anti-CD20 antibody Rituximab was evaluated by flow cytometry as follows: cells were 
grown according to the ATCC protocol, centrifuged at 500 x g for 10 minutes at room 
temperature, then resuspended to approximately 5x105 cells per 100 ul in Dulbecco’s 
PBS, pH 7.5 (dPBS, Thermo, SH30028.02) with .1% BSA (dPBSB).  Cells were then 
incubated with 10 ug of Rituximab (generously provided by Dean Lee, MD Anderson 
Cancer Center) per 106 cells for 1 hr at 4°C while rotating. Antibody sensitized cells were 
centrifuged at 500 x g for 10 minutes at room temperature, washed by resuspending with 
dPBSB and then in dPBS 2X.  Following washing and centrifugation, aliquots of 105 
cells were resuspended in a mixture of 40 ul of NHS, 55 ul of gelatin veronal buffer, and 
15 ul FAB antibody or C1-inh in dPBS resulting in a final concentration of 25 uM, and 
then incubated for 45min at 37°C while rotating. After incubation, cells were washed by 
centrifugation at 500 x g for 10 minutes and resuspended in dPBS and then in dPBSB 2X. 
The deposition of C3c on the surface of the cells was determined with 100ul of 1/20 
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FITC labeled C3c antibody (Abcam, ab4212) in dPBSB for 30min at 4°C. Cells were 
washed again with dPBSB and FITC signal was analyzed using BD FACS-Aria flow 
cytometer.  
Complement mediated lysis of Ramos cells in the presence of either FAB or C1-inh 
was determined by calcein release upon lysis. Cells were loaded with Calcein by 
incubating 5x105 Ramos cells in 1 ml PBS, pH 7.5 with 4uM calcein-AM (Sigma, C1359) 
at 37°C for 45 minutes. The cells were then washed 2X with PBS, pH 7.5 by 
centrifugation at 500 x g for 10 min followed by resuspension in 1 ml PBS, pH 7.5. 
Aliquots of 105 cells were resuspended in a mixture of 120 ul NHS, 120 ul gelatin veronal 
buffer, and 60 ul of a solution of FAB antibody or C1-inh in PBS, pH 7.5 resulting in final 
concentrations between 9.2 and 1.8 uM. 100 ul aliquots of cell suspension were 
transferred to 96 well round bottom plates (Costar, 3799), supplemented with 5 ul of 2 
mg/ml Rituximab in PBS, pH 7.5 and incubated for 25 minutes at 37°C with mild 
shaking. Following incubation, cells were pelleted at 1000 x g for 5 minutes then 50 ul of 
supernatant was transferred to flat bottom optical plates (Thermo Fisher #265301) 
containing 50ul of PBS, pH 7.5. Calcein release was measured by reading the 
fluorescence of supernatant using a microplate reader with 485nm excitation and 535nm 
emission.   
 The percent of specific calcein release was determined by the following 
equation:  
 %  Specific  Release  = !"#$  !"#"$%" !(!"#$%&$'#()  !"#"$%")!"#$%&%  !"#"$%" !(!"#$%&!"#$%  !"#"$%") 
 
Incubating cells in serum/inhibitor solution without rituximab determined 
spontaneous release. Maximum release was estimated by incubating cells in 2% Triton 
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X-100 (Sigma T8787). Relative cell lysis was determined by dividing the specific percent 
release from test wells by the percent specific release from wells with Rituximab 
antibody and no inhibitor.  
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Chapter 3 
 Characterizing Humanized Mice 
 
INTRODUCTION 
 
Humanized mice are generated through the engraftment of human CD34+ 
hematopoietic stem cells into immune-deficient mice. Once engrafted, the human stem 
cells home in to the bone marrow where they divide and differentiate into human cells of 
the myeloid and lymphoid lineages (45). Humanized mice are rather difficult to use 
because engraftment requires expert training and the level of lymphoid and myeloid cells 
formed post engraftment is quite variable. Nevertheless, they are highly utilized in 
biomedical research because these mice provide an unparalleled opportunity to study 
human cells and biological processes in vivo (124). In particular, humanized mice provide 
an important preclinical model that enables the investigation of human-specific infectious 
diseases in order to better understand the mechanism of disease pathogenesis and 
evaluate therapeutics (44). One of the predominant applications of humanized mice has 
been the study of diseases such as HIV, Dengue virus and Epstein-Barr virus (EBV) 
infections (125-127). Detailed understanding of the B cell repertoire produced in these 
mice has significant relevance to human immunology and the study of human-specific 
diseases in addition to being a potential source of fully human antibodies. 
Since initial development of humanized mice, continued improvements in the 
mouse strains used for engraftment have resulted in the systematic reduction of mouse 
immune cells thereby allowing improved development of human lymphocyte populations 
in the animal (45). Reduction in background immune cell production in the host is 
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important to prevent competition with, or rejection, of engrafted human CD34+ cells. One 
of the most popular mouse strains developed to date, and the one used in this research, is 
termed NSG (NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ mice). The PRKDC gene encodes a protein 
that resolves DNA strand breaks that occur during V(D)J recombination, resulting in 
significantly reduced numbers of T and B cells (47). Disruption of the IL-2R common γ 
chain (γc) results in a loss of NK, B and T cells and dendritic cell dysfunction since γc is 
required for multiple cytokine signals that are indispensible to immune cell development 
(IL-2, IL-4, IL-7, IL-15, etc) (45) .12 weeks after engraftment of human CD34+ stem 
cells into NSG mice, the lymphocyte progenitors  develop into the full population of 
human immune cells (49-51). However, immune cell development from mouse to mouse 
is heterogeneous and dependent on the quality of CD34+ stem cells and the skill in which 
they are engrafted. Therefore, we seek to characterize the human immune cells that 
develop in NSG mice and the immune response they generate following immunization. 
We analyzed the B and T lymphocyte subpopulations that develop either 6 or 12 
weeks post engraftment in NSG mice engrafted with human CD34+ HSC cells.  Repeated 
immunizations with a highly immunogenic antigen failed to yield significant antigen-
specific IgM or IgG antibodies in these mice. Mice were characterized with florescent 
antibodies that bind cell surface markers that indicate cell type (see Figure 3.4 and Table 
3.1). Important cell types determined in this study were CD3+ T cells including the CD4+ 
helper and CD8+ cytotoxic T cell subtypes, as well as CD20+ B cells including the CD27+ 
memory B cell and CD138+ plasma cell subtypes.  Based on these results, we conclude 
that NSG humanized mice are suitable for studying naïve mature B cells and T cells, 
however they are not suitable for the analysis of activated B-cell subsets in response to 
immunization. 
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RESULTS 
FACS Scans for Characterization of Humanized Mice Lymphocytes 
10 Non-obese diabetic-scid-IL2Rγnull (NOD-scid- IL2Rγnull) mice were engrafted 
with umbilical cord blood (UCB) CD34+ hematopoietic progenitors and analyzed at 
either 6 weeks or 12 weeks post engraftment. Spleen, bone marrow and thymus (when 
present) were collected, labeled with flourochrome conjugated antibodies as discussed 
later, and analyzed using flow cytometry (FACS Aria). Peripheral blood (PB) and lymph 
nodes (LN) lymphocytes were too few to analyze via flow cytometry.  
Human lymphocytes express the surface protein CD45+ cells. Cells labeled with 
an anti-CD45 antibody, and therefore correspond to total human lymphocytes in the 
mouse, were quantified via FACS from the spleen for both the 6 and 12-week-old mice 
populations. The frequency of CD45+ cells varied among the 6 and 12-week post 
engraftment mice. CD45+ human lymphocyte frequencies from the total spleen 
population were 10% ± 7% in six-week-old mice and 34% ± 37% (between 1-90%) in the 
same population in twelve-week-old mice.  From each spleen, CD3+ T lymphocytes 
comprised <2% of CD45+ cells in the spleens of mice analyzed six-weeks-post 
engraftment mice and 32% ± 22% in mice analyzed twelve-weeks post engraftment, 
suggesting maturation of T-cells largely occurs after 6-weeks following engraftment. In 
contrast, the fraction of CD20+ B cells within each spleen was surprisingly consistent: 
CD20+ B cells comprised approximately 50% ± 10% of CD45+ human lymphocytes in 
the spleen from both 6 and 12-week-old mice.  
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Figure 3.1: FACS scans of the spleen of a representative a 12-week-old humanized mouse. Results representative of N=4 12 
week old humanized mice. CD45+ / CD3+ T cells from panel (A) were further analyzed in panel (B) for CD4+ T 
helper cells and CD8+ cytotoxic T cells. CD45+ / CD20+ B cells from panel (C) were further analyzed in panel (D)  
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Figure 3.2:	  Engraftment levels and T cell populations from the spleen of humanized 
mice at different ages.  
 
Figure 3.3: Engraftment levels and B cell populations from the spleen of humanized 
mice at different ages 
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The spleen, thymus (when present) and bone marrow from twelve-week old mice 
were further analyzed via antibody staining and FACS for the presence of specific B-cell 
and T-cell subtypes and other CD45+ lymphocytes. Of CD20+ B cells, approximately 
5.7% ± 1.8% of the spleen B cells and 1.3% ± 1.0% of the bone marrow B cells were 
CD27+ B memory cells; 13.3% ± 5.7% of the spleen and 15.7% ± 3.5% bone marrow 
CD20+ B cells were CD38+ plasma cells. Of the CD3+ T lymphocytes analyzed, the 
thymus contained predominately CD4+/CD8+ developing T lymphocytes, while T cells 
that had migrated to the spleen had largely differentiated into CD4+ helper T cells or 
CD8+ cytotoxic T cells.   
Non-B and T-cell leukocytes were also analyzed. CD11c+ dendritic cells, which 
mainly function as antigen presenting cells, were present at 2.3% ± 1.3% and 2.35% ± 
1.2% in the spleen and bone marrow respectively. CD33+ monocytes, mast cells and 
myeloid progenitors, which are non-lymphoid white blood cells that play other roles in 
immunity, are present at 4.2% ± 1.9% and 12.1% ± 6.3% in the spleen and bone marrow 
respectively. These leukocyte development levels are nearly identical to those published 
by Ishiwaka et al (50).  
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Figure: 3.4: Engraftment Levels of Leukocytes in 12-week-old humanized mice determined by FACS. (A) T-cell engraftment 
levels and subsets. CD8+ and CD4+ cells are reported as a percent of CD3+ population. (B) B cell engraftment 
levels and subsets. CD20+ engraftment levels are reported as a % of the total CD45+ population; CD27+ and 
CD38+ subsets of B cells are reported as a percent of CD20+ B cell population. (C) Other leukocyte subsets. 
Engraftment levels of human subsets are reported and a percent of the CD45+ population.  
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Immunizations of Humanized Mice 
The 10 Non-obese diabetic-scid-IL2Rγnull (NOD-scid- IL2Rγnull) mice were 
engrafted with umbilical cord blood (UCB) CD34+ hematopoietic progenitors. 12 weeks 
post- engraftment, mice were immunized into the peritoneum with an emulsion of 50ug 
of the highly immunogenic protein Concholepas concholepas hemocyanin (CCH) and 
complete Freund’s adjuvant (CFA). Each mouse received a subcutaneous booster 
injection 3 weeks later composed of an emulsion of 50ug of CCH and incomplete 
Freund’s adjuvant (IFA). Two weeks after boost immunization, blood was drawn from 
the mice via tail vein snip and an ELISA was performed to measure IgG and IgM 
antibody titers against CCH.  
IgM and IgG antibody titers were determined as 3-fold above background OD450 
reading for each of the 10 mice. Each mouse produced antigen specific antibodies at 
lower than 1/1,000 dilution, indicating a significantly reduced ability to produce human 
antigen-specific antibodies. Standard laboratory BALB/c mice immunized in this fashion 
produce antibody titers between 1/50,000 and 1/500,000.  
  
 90 
 
 
Figure 3.5: CCH-specific antibody titers for mice at following two immunizations. The 
numbers in the legend represent the identity of the humanized mouse. IgM 
and IgG (cross reactive detection antibody was used) antibody titers are 
determined as the point where signal is 3-fold above background OD450 
signal. Therefore, none of these mice have antibody titers higher than 1000.  
 
DISCUSSION 
Here we analyzed the lymphocytes and immune responses in humanized NSG 
((NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ ) 6- and 12-weeks post-engraftment. For the 12-week 
old mice studied in this work, numbers for dendritic cells, B cells and T cells 
appropriately reflect engraftment levels observed previously 12-weeks post engraftment 
by Ishikawa et al. (50). Their results did show slightly more B cells, (ex. 47% ± 12% in 
the spleen in our studies vs 60% ± 14% in their work), however they used a different B 
cell marker (theirs CD19 vs CD20 ours) that may explain the different levels recorded. At 
6-weeks, CD3+ T cells were nearly non-existent but CD20+ B cells were found in 
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significant numbers; by 12-weeks post engraftment both cell types were present at levels 
in agreement with previously published data.  
The numbers of mouse CD45+ cells were inversely correlated with human CD45+ 
cells in the animals. We suspect that the presence of murine CD45+ cells is a result of 
insufficient ablation of host CD45+ cells during γ irradiation of pups. It is poorly 
understood how murine CD45+ cells develop (the IL2-Rγ mutation should prevent them 
from developing), these cells have been recorded before in previous studies 
characterizing NSG mice (50). Therefore, this result underscores the importance of 
expertise required in order to achieve high engraftment levels and the necessity to 
characterize each mouse within the study.  
The lymphocytes cells produced in NSG mice are sufficient to elicit a T and B 
cell response following antigen stimulation (50). However, previous studies have found 
that despite the presence of a total >106 CD20+ B cells and CD3+ T cells in the spleen, 
antigen specific IgG titers are nearly undetectable following immunization in this animal 
model (50, 128). One reason thought to be partially responsible for the weak antibody 
response is that human T cell selection occurs against murine MHC I / II thereby altering 
human T cell help to mature B lymphocytes (129). Additionally, previous accounts 
describing the mature naïve B cell subsets generated in NSG humanized mice have not 
thoroughly characterized the B cell antibody repertoires in depth.  
Follow up work on these mice using identical procedures and flourochrome 
labeled antibodies that detect B-cell development stage (CD19, IgM, IgD), revealed that 
~90% of the B cells were IgM/IgD+, indicating the B cells were naïve (53). Similar 
results, indicating normal naïve adaptive immune cells but little production of antigen 
specific antibodies, have been found in similar mouse strains (50, 130, 131). Results from 
Watanabe et al. using the similar mouse strain NOD/shi-scid/γcnull (NOG) further 
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investigate the B-cell development (131). We therefore concluded that naïve mature B 
cells developed in these mice were suitable for antibody repertoire study. Follow up work 
confirms that the B cell repertoire is indeed very similar to the native human repertoire 
(53). 
Following repeated immunization of these mice, we saw nearly negligible antigen 
specific IgG and IgM antibody titers. Subsequent published studies confirm the lack of 
antigen specific antibodies produced using humanized mice (50, 128). We therefore 
concluded that insufficient IgM/IgG development in response to immunization excluded 
the mature repertoire from further study. Improvement of the milieu provided by the host 
mouse strain is necessary in order to achieve a functional human adaptive immunity in 
mice. One such innovation is the transgenic mouse strain NGS-HLA-A2/HHD, which has 
backcrossed the human HLA class I transgene onto the NHS background (129). This 
improvement is significant because these mice have a humanized immune 
microenvironment expressing HLA class I, allowing for the mouse facilitate proper 
intrathymic selection of human T cells in a HLA-restricted manner and thereby resulting 
in active cytotoxic T lymphocytes and CD4+ T helper cell subsets. Another promising 
improvement to B cell survival is the introduction of the human B lymphocyte survival 
factor, BLyS, which is shown to increase serum Ig levels 40-fold in response to thymus-
independent antigens (132). Therefore, we suspect that in the near future, humanized 
mouse strains improvements or supply of exogenous survival factors will support a more 
complete human adaptive immune response in mice, capable of producing significant 
quantities of antigen specific IgG.  
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MATERIALS AND METHODS 
Ethics Statement 
The animals used in this study were housed in under pathogen-free barrier 
conditions at the Animal Resource Center at the University of Texas at Austin. The 
experiments were conducted following the Institutional Animal Care and Use Committee 
guidelines (approved protocol number AUP-2009-00035). 
 
Engraftment of Humanized Mice 
NOD-scid- IL2Rγnull mice were irradiated at 1-2 days old with 100cGy of gamma 
irradiation laregly following the protocol of Pearson et al. (48). Intracardiac injection of 
3x104 Umbilical Cord Blood CD34+ hematapoetic progenitors (Lonza, 2C-101A) in 50ul 
of PBS, pH 7.5 was performed once mice were irradiated.  
 
FACS Scans 
At 6-12 weeks post engraftment, spleen, bone marrow from the tibia and fibia, 
and thymus were collected into ice cold buffer 1 (PBS, pH 7.5, 0.1% BSA, 2mM EDTA). 
A single cell suspension was made from isolated organs by passing cells through a 70uM 
strainer into a 50mL conical tube (large gauge needles and the rubber stopper of a 3mL 
syringe are extremely helpful to break up the organ and allow single cells to pass). An 
additional 5ml of buffer 1 was used to rinse strainer. Cells were then centrifuged at 500 x 
g for 10 min in a swinging bucket rotor and resuspended in 1ml of buffer 1.  
Washed cells in 1ml of buffer 1 were incubated on ice for 5 minutes with 2ul of 
FC Block. Following block, 100ul aliquots of cells were incubated with flourochrome-
labeled antibody panels according to the table below then incubated for 20 minutes at 
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4°C, centrifuged at 500 x g for 10 min, resuspended in 100ul of buffer 1, and analyized 
via FACSAria flow cytometer. Analysis was performed using FACS Diva software.  
 
 
T-cell 
Panel   Vendor Prod # vol (ul)/aq 
V450 huCD45 human leukocytes BD-pharma 560367 5 
FITC huCD3 T Cells BD-pharma 555332 20 
PE huCD4 CD4+ T cells BD-pharma 555347 20 
APC huCD8 CD8+ T cells BD-pharma 555369 20 
      
      
 
B cell 
Panel   Vendor Prod # vol (ul)/aq 
V450 huCD45 human leukocytes BD-pharma 560367 5 
FITC huCD20 B cells BD-pharma 555622 20 
PE huCD38 plasma cells e-bioscience 12-0388-42 5 
APC huCD27 memory cells BD-pharma 558664 20 
      
      
 
Characterization Panel Vendor Prod # vol (ul)/aq 
V450 huCD45 human leukocytes BD-pharma 560367 5 
FITC huCD11c dendritic cells e-bioscience 11-0116-73 20 
PE huCD33 myleoid cells BD-pharma 555450 20 
APC mCD45 mouse leukocytes BD-pharma 559864 2 
      
      None Fc Block Block Mouse FcR BD-pharma 553142	   2 
Table 3.1: Panels of Antibodies used for various characterizations. 
 
Immunizations 
12 week old humanized mice were immunized with an emulsion of 1/3 adjuvant 
complete Freund’s adjuvant (CFA) with 50ug of antigen Concholepas concholepas 
hemocyanin (CCH) (Pierce, 77130) in dPBS, pH 7.5 (Thermo, SH30028.02) was 
prepared at RT by mixing with a pipette then brief sonication until a stable emulsion is 
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achieved (usually 30 seconds). Injection agent was drawn into the 29G syringe (BD, 
309306) and mice were immunized subcutaneously into the scruff of the back of the 
neck. Booster immunizations were performed via intraperitoneal injection three weeks 
after primary immunizations with Incomplete Freund’s adjuvants (IFA) instead of CFA 
and 50ug of CCH protein in 50ul of PBS, pH 7.5.  
 
Titer Determinations 
Mice were bled 2 weeks post boost via tail vein snip, then serum IgG and IgM 
titers were determined by ELISA serial dilution. Briefly, high binding ELISA plates 
(Corning Costar 3590) were coated overnight at 4C with 50ul of 4ug/ml antigen in PBS, 
pH7.5. Plates were aspirated then blocked for 3 hours at 25°C with PBS, pH7.5, 2% milk. 
Plates were again aspirated then incubated with 50ul of serum diluted 1/200 through 
1/437000 in PBS, pH7.5, 2% milk and incubated at 25°C for 2 hours. Plates were washed 
3X with PBS, pH 7.5 0.05% tween-20 (PBST) then incubated with 1/5000 anti-Mouse I 
HRP (Jackson Immuno, 109-035-044) at 25°C for half an hour.  Plates were washed 
again 3X with PBST then incubated with 50ul of TMB substrate for 15 min at 25°C then 
quenched with 1M sulfuric acid. Plates were read at 450nm and analyzed with GraphPad 
Prism software. Titers were determined as the point where the non-linear fitted curve 
determined 3-fold signal above background.  
The lack of an antigen-specific antibody response following repeated 
immunizations with a highly immunogenic adjuvant suggests that only a partial 
reconstruction of the human adaptive immune system was achieved. Therefore, we 
conclude that NSG humanized are suited for studies requiring a naïve human adaptive 
 96 
immune system, but further improvements in the host mice are necessary in order to 
study the adaptive immune response.  
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Chapter 4 
Generating Highly Polarized Antibody Repertoires in Immunized Mice 
 
INTRODUCTION 
Mice have been used as the primary source for generation of monoclonal 
antibodies since the mid-1970s when hybridoma technology was invented (34). The 
hybridoma technology involves fusing antibody-producing cells from the spleen of an 
immunized mouse with myeloma cells in order to produce antibody-secreting cells that 
can survive indefinitely, thus enabling an unlimited production of a single antibody (33). 
Limitations of the technology are that it is time consuming and often only 2-3 distinct 
monoclonal antibodies per animal are isolated. Innovations in the field of therapeutic 
technology, specifically the development transgenic mice with human antibody variable 
genes, have made the industry even more dependent on mice for production of 
therapeutic antibodies, not less (117, 133). The hybridoma technology is still widely used 
today because it is a straightforward and effective, albeit laborious, process for producing 
antibodies to a desired antigen. The use of hybridoma technology as they did in the 1970s 
has significant disadvantages for the production of therapeutic antibodies. Therefore, a 
technology that circumvents the slow culturing process while maintaining or improving 
the simplicity and efficacy of antibody discovery from immunized mice is highly 
desirable.  
Reddy et al. recently published an antibody discovery technology that avoids the 
laborious and time consuming screening and culturing procedures of hybridoma 
technology. Their technology demonstrated that the most highly represented heavy and 
light V gene sequences from the antibody repertoire isolated from the bone marrow 
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plasma cells are antigen specific (105). Following repeated immunization of mice and 
isolation of the bone marrow plasma cell population (BMPC) via FACS sorting, the most 
frequent antigen specific V genes from the sequenced antibody variable region repertoire 
were synthesized, expressed either as scFvs or full length IgGs in bacteria or mammalian 
cells, and specificity was verified via ELISA.  
Reddy et al. showed that the most abundant antibody V genes (.5-10% frequency) 
expressed by bone marrow plasma cells (BM-PCs) 7 days post-boost immunization 
correspond to antigen-specific antibodies. However, not all highly frequency V genes in 
the BM-PC repertoire are antigen specific necessitating the testing of several 
combinations of the most frequent VH and VL genes to find antibodies with desired 
affinity and specificity. Therefore, in order to increase the speed and simplicity of a 
frequency-based antibody discovery technique, it is desirable to create polarized 
repertoires composed of a higher frequency of antigen specific antibodies and less 
irrelevant antibodies. The purpose of this study is to investigate a new method for the 
generation of even more polarized repertoires composed of antigen specific antibodies for 
use in the discovery of antigen specific antibodies.  
Reddy et al. utilized the well-established fact that plasma cells in the bone marrow 
produce antigen-specific antibodies that constitute the steady-state serological response to 
challenge or immunization (28). The cytokines and other signals present in the bone 
marrow environment allow plasma cells to reside there for more than 60 days in mice 
(134). Without survival signals, antibody secreting cells such as plasma cells and 
plasmablasts survive for an average of one week (135). Because the long-lived plasma 
cells will find residence in the bone marrow irrespective of which secondary lymphoid 
organ(s) they were selected for expansion and differentiation in, the bone marrow niche is 
filled with antibody producing cells targeting the large array of antigens to which a 
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mouse has been exposed, presumably during its entire lifetime up to that point (136, 137). 
It follows that selection of relevant antigen-specific plasma cells from the bone marrow 
will be complicated by the many other plasma cells present that do not produce an 
antibody specific to the antigen of interest, thereby diluting the repertoire with antibodies 
that bind irrelevant antigens.  
The bone marrow is the eventual destination of most long-lived plasma cells, but 
it is not the anatomical location where plasma cell selection occurs. The origin of these 
cell types is a germinal center within a lymph node or the spleen. Germinal centers 
provide a cellular milieu for the expansion, differentiation and affinity maturation 
(through somatic mutation of the antibody genes) of mature B cells (25). Both the lymph 
nodes and bone marrow contain plasma cells that produce antibodies specific to the 
antigen (138). However, only the bone marrow has the signals necessary to sustain long 
lived plasma cells (135). Among the important signals found within the bone marrow that 
extend the life of the antibody producing plasma cells include CXCL12, TNF, IL-5, IL-6 
and ligands for CD44 (135).  
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Figure 4.1: Antigen recognition and B-cell expansion initially occurs in the spleen or 
lymph node. Following recognition and expansion of antigen specific B 
cells, plasma blasts are generated which leave the lymph nodes and spleen 
and eventually travel to the survival niche present in the bone marrow (135). 
 
Figure 4.2: The bone marrow contains the appropriate environment for long-term 
persistence of IgG secreting plasmablasts and plasma cells thus promoting 
the persistence of these cells. However, the spleen or other secondary 
immune response sites do not contain the environment necessary for long 
term persistence of antibody producing cells (135).  
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Plasmablasts generated by the lymph node germinal center reaction no longer 
express the chemokine receptors CXCR5 and CCR7 that are expressed in the germinal 
center B cells from which they are derived; the loss of expression of these receptors is 
thought to allow them to leave germinal centers and become migratory (139). Nascent 
plasmablasts express instead CXCR4 and CXCR3 (the later of which occurs when the 
formation of plasmablasts is stimulated by the presence of interferon-γ), thereby 
attracting the cells from the lymph nodes to the bone marrow and inflamed tissue (139). 
A lymph node where lymphatic vessels carrying the antigen drain into is expected to 
contain germinal centers formed by antigen-stimulated B cells.  Hence, that lymph node 
is unlikely to contain many antibody-secreting cells to unrelated antigens from prior 
exposure(s). Therefore, the repertoire of the local environment of a targeted lymph node 
should be filled with a much greater fraction of antigen specific antibody producing cells 
than the bone marrow. Experimental analysis confirms that extremely high levels of 
background antibody producing cells are present the bone marrow; quantification of the 
antibody producing cells from various anatomical locations of unimmunized mice shows 
that >70% of antibody producing are found in the bone marrow, while less than 3% of 
these cells are found in the lymph nodes (140).  
In order to avoid the many irrelevant antibody-producing cells present in the bone 
marrow, we sought to generate highly polarized antibody repertoires composed largely of 
antigen specific antibodies by generating an antigen specific immune response in a 
specific lymph node. In order to target a specific lymph node with antigen, we 
immunized mice by injecting antigen and adjuvant into one of the rear footpads. Upon 
immunization, antigen was delivered via the lymphatic system to the popliteal lymph 
node located at the knee of the animal.  
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Figure 4.3: Targeting specific lymph nodes varies by injection route(141). Targeting the 
footpad in panel A results in antigen delivery to the popliteal lymph node 
(PO) and subsequently to other lymph nodes downstream from the PO.  
 
Specific lymph nodes have previously been targeted with antigen in order to 
localize antigen-specific B cells for development of hybridoma fusions. Hybridomas 
produced from a splenic B-cell fusion effectively produce specific antibodies at wildly 
different frequencies; it is common to see reports that 1% -99% of successful fusions 
produced by a splenic B-cell fusion are antigen specific (142). However, most 
publications report that less than 10% of successful fusions generated from the spleen of 
an immunized mice are antigen specific (143). In order to improve the frequency of 
antigen specific hybridomas generated, researchers have targeted the popliteal lymph 
node by immunizing mice into the footpad. Targeting is effective because dendritic cell 
trafficking is regional and consequently antigen uptake by these cells at a distinct 
anatomic location leads to maturation and antigen presentation at the closest draining 
lymph node. Localization of antigen presentation at the lymph node nearest the site of 
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immunization leads to high levels of antigen-specific B cells. One study found that 
hybridomas developed from targeted popliteal and inguinal lymph nodes after 
immunizing into the proximal footpad produced only antigen specific clones (384/384) 
compared with only 8% antigen specify (29/352) from hybridomas developed from the 
spleen following a IP immunization (143). 
 
 
Table 4.1: Fusion efficiency of hybridomas developed from different anatomical origins. 
(143)  
Targeting the popliteal lymph node for antibody discovery has been validated in 
subsequent studies (144, 145). Sado et al. also used lymph node targeting in order to 
generate antigen-specific hybridomas, however they targeted a different lymph node via 
tail vein injection. In their study, Sado et al. reported that 100% of the hybridomas from 
the targeted lymph node were antigen specific, while conventional spleen isolations 
yielded only 10% of antigen specific hybridomas (146). Antigen specific hybridomas 
have also been discovered in rats via popliteal lymph node targeting through footpad 
injection (147).  
 Based on these published results, anticipated that lymph node targeting would be 
an effective method to generate highly polarized libraries of antigen specific-antibodies. 
In initial studies to test this hypothesis, we immunized animals in the rear footpad with 
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the hapten phosphorylcholine (PC) conjugated to protein carrier BSA. Phosphorylcholine 
antigen is a highly immunogenic hapten commonly found covalently attached to LPS on 
the surface of many bacteria including Streptococcus pneumoniae, Pseudomonas 
aeruginosa, and Neisseria species (148). PC-BSA is an ideal proof-of-principle antigen 
because it produces a highly skewed immune response in certain mouse cell strains. 
When BALB/c mice are immunized with PC, >90% of antigen-specific antibodies 
produced from the primary immune response in this strain comprise a specific heavy 
chain V-D-J combination (V S107.1, D FL16.1, J JH1) (149, 150). A major advantage of 
using PC hapten is that the antigen-specific sequence is already known; therefore, 
relevant antibodies are visualized easily by DNA sequencing in silico thus it is not 
necessary to experimentally determine which antibody DNA sequences would yield 
antigen specific antibody proteins.   
Following primary footpad immunization of two BALB/c mice with PC-BSA, we 
used PCR and Sanger sequencing of the antibody variable genes to investigate the 
repertoire of antibodies found in the targeted popliteal lymph node. PCR analysis of 
cDNA demonstrated that the targeted lymph node (ipsolateral to the site of injection) 
contained cells expressing IgG, while the control lymph node (contralateral to the site of 
injection) did not produce detectable levels of IgG. Furthermore, sequencing of the heavy 
chain V-gene repertoire revealed that mRNA transcripts isolated from the antigen-
targeted lymph nodes were >20% of the heavy chain component of phosphorylcholine-
specific T15 idiotype antibody. Therefore, the antibody repertoire from a lymph node 
targeted with hapten antigen is highly polarized with antigen-specific antibodies, 
allowing for simple in silico selection of antigen specific antibodies. We expect that this 
work will be the foundation of an overall improved protocol for monoclonal antibody 
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discovery that accelerates the speed and enhances the simplicity of therapeutic antibody 
discovery. 
Because most therapeutically relevant antibodies bind complex protein targets, we 
applied the lymph node targeting technique to a complex antigen by repeatedly 
immunizing two additional BALB/c mice with Ebola virus-like-particles (VLPs) 
expressing the recombinant Ebola capsid glycoprotein-1 (GP1). Through PCR analysis of 
lymph node cDNA, we demonstrated that the targeted lymph nodes contained cells 
expressing IgG, while the control lymph node did not contain detectable levels of IgG. 
Furthermore, Sanger sequencing analysis of the antigen targeted lymph nodes revealed a 
highly polarized repertoire in one mouse ( >20% of the antibodies corresponded to one 
heavy chain sequence) and a moderately polarized repertoire in another mouse ( >5%). 
These results suggest that multiple immunizations with a complex antigen targeted at a 
specific lymph node will elicit a highly polarized antibody repertoire. However, 
additional work (discussed at the end of this chapter) is required in order to validate the 
antigen specificity of the highly represented antibody heavy chains from the Ebola VLP 
immunized mice.  
 
RESULTS 
PCR analysis of mRNA from PC-BSA Antigen Targeted Lymph Nodes 
Two mice BALB/c mice were immunized in the footpad with 25ul of 20ug of PC-
BSA (16 PC molecules per BSA) in PBS, pH 7.5 with 8ul of Titer Max Gold adjuvant. 
Both the antigen targeted and control popliteal lymph nodes were collected and processed 
10 days after primary immunization. After harvest and CD138+ cell subtype selection via 
MACS, cDNA was generated from each cell fraction isolated from either the lymph node 
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or the spleen. PCR was performed on cDNA generated from the targeted popliteal lymph 
nodes and their control counterparts on the opposite foot in order to establish which 
relevant mRNA transcripts are present in the lymph node after targeting with an antigen. 
IgG, IgM, PC specific idiotype T15 and GapDH (a housekeeping gene) were analyzed 
via PCR with specific primers, resolved on a 3% agarose gel, then inspected under UV 
light.  Both the targeted and control lymph nodes had sufficient levels of IgM and 
GapDH (a housekeeping gene) that they produced visually detectable bands of PCR 
product when resolved gels were run under UV light. Additionally, each of the targeted 
lymph nodes generated visually detectable PCR product bands when cDNA was 
amplified by a PCR reaction with IgG and PC-specific T15 primers, while the control 
lymph nodes did not. These PCR results demonstrate that targeted lymph nodes fill with 
antigen specific cells that have class switched to IgG, while the control lymph nodes do 
not. While these results do not confirm that all the IgG produced in the targeted lymph 
node are antigen specific, the prominence of the IgG and T15 bands suggest that there are 
many antigen specific clones in the targeted lymph node. However, a sequence-based 
approach is required in order to determine the relative frequency of antigen specific 
clones produced by the targeted lymph node. 
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Figure 4.4: Comparing products on a gel from PCR reactions with specific primers (top 
line) using the cDNA from the targeted (proximal, or lateral, to the site of 
injection) and control (distal, or contralateral, to the site of injection) 
popliteal lymph node from mice immunized with PC-BSA.  
In order to compare cell types and antibody specificities from the targeted lymph 
node and spleen, cDNA was created from the CD138+ cells (plasma cells) isolated from 
each organ from mice immunized with PC-BSA. These semi-quantitative PCR band 
results indicate higher mRNA transcript levels of antigen-specific T15 antibody in the 
targeted lymph node compared to the spleen. Additionally, the PCR results also indicate 
that the quantity of IgG mRNA transcripts is much higher in the lymph node than the 
spleen. These results suggest that the targeted lymph node has a much higher frequency 
of cells producing antigen specific IgG compared to the spleen, thus making the lymph 
node an ideal anatomical site for the discovery of antibodies.  
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Figure 4.5: Comparing products on a gel from PCR reactions with specific primers (top 
line) using the cDNA from the targeted lymph node plasma cells and the 
plasma cells from the spleen of mice immunized with PC-BSA.  
 
Sequencing Analysis of Lymph Nodes Targeted with PC-BSA 
Heavy chain sequences collected from the CD138+ cells of the targeted lymph 
node and the spleen were analyzed in order to determine the frequency of the heavy chain 
component of phosphorylcholine-specific T15 idiotype from the primary immune 
response to phosphorylcholine immunization via the footpad. In order to amplify these 
genes from cDNA, we used standard PCR conditions with a 5’ primer mix composed of 
primers specific for the entire heavy chain V gene repertoire and a 3’ primer mix 
composed of primers specific for the constant region of each IgG subclass. After 
digesting, ligating into the APEx vector, and transforming PCR products using standard 
cloning techniques, individual colonies were sequenced via Sanger sequencing and the 
frequency of the heavy chain component of phosphorylcholine-specific T15 idiotype was 
determined (77).  
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SPPC	  
Mouse	  1	  
LNPC	  
Mouse	  1	  
SPPC	  
Mouse	  2	  
LNPC	  
Mouse	  2	  
T15	  seq	   0	   3	   0	   8	  
Total	  #	  of	  seq	   43	   33	   32	   36	  
%T15	   0%	   9%	   0%	   22%	  
Table 4.2: A comparison of T15 idiotype frequencies from two mice immunized with 
PC-BSA. SPPC = Spleen plasma cells, LNPC = lymph node plasma cells 
These results indicate that the targeted lymph node has a much higher relative 
frequency of antigen-specific plasma cells than the spleen. In addition to the CD138+ 
subset, the mRNA from the whole lymph node was also collected and tested for the 
presence T15 IgG in the same manner as the CD138+ subset. Analysis of heavy chain V 
gene sequences generated from whole lymph node revealed that the IgG mRNA 
transcripts had two-fold more T15 sequences than the CD138+ subset. This is likely due 
to the contribution of other phosphorylcholine specific-cell subtypes such as CD138-low 
plasmablasts, CD138-negative memory cells and CD138-negative germinal center cells. 
Therefore, future investigations of sequence frequency should use whole lymph node 
mRNA in order to maximize polarization of the antibody repertoire.  
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Total	  LN	  	  
Mouse	  1	  
Total	  LN	  	  
Mouse	  2	  
T15	   10	   22	  
Total	  Sequences	   46	   42	  
T15	  %	  of	  total	   22%	   52%	  
Table 4.3: T15 idiotype frequency identified from IgG cDNA transcripts from the entire 
lymph node of two mice sacrificed 10 days after primary immunization.   
It is interesting to note that the many T15 variable heavy chain regions sequenced 
were associated with various IgG subclasses with IgG1 and IgG2b were being the most 
frequent.  
 
Antibody Titer and PCR analysis of mRNA from Ebola-VLP Hyper Immunized 
Mice 
25 ug of Ebola virus like particles (VLPs) in 20ul PBS, pH 7.5 with 10ul of Imject 
Alum adjuvant (Pierce 77161) were injected into the footpad of two BALB/c mice on 
days 0, 21, 35 and 49.  Ebola VLP specific IgG antibody titers were determined 7 days 
after each injection by collecting serum by tail vein bleed and performing an ELISA. 
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Figure 4.6: Ebola VLP Immunization Response to footpad injection: Serum IgG titers 
are reported for each day recorded. Red lines indicate boosts at days 21, 35 
and 49.  
At day 56, spleen and popliteal lymph node CD138+ cells and whole lymph node 
cells were isolated and cDNA was created as described for PC-BSA immunized mice in 
the previous section. PCR was performed on the cDNA generated from the targeted 
popliteal lymph nodes and their control counterparts on the opposite foot with primers 
specific for the constant regions of IgM, IgG and GapDH. PCR reactions were resolved 
on a 3% agarose gel then bands were inspected under UV light 3%. As with the PC-BSA 
immunized mice, visually detectable IgG bands were only present in the lymph node 
targeted with antigen. While these results do not confirm that all the IgG produced in the 
targeted lymph node are antigen specific, the prominence of IgG and the similarity of the 
response to the PC-BSA/T15 response suggest that there are many antigen specific 
antibody-producing cells in the Ebola VLP targeted lymph node. However, a sequence-
based approach is required in order to determine the relative polarization of antibody 
mRNA transcripts within the targeted lymph node and high frequency antibodies should 
to be tested via ELISA in order to determine antigen specificity. 
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Figure 4.7: PCR bands from whole lymph node (LN) cDNA of two mice hyper 
immunized in the footpad with Ebola VLPs using specific primers for the 
constant regions of antibody heavy chains or GapDH.  
 
Sequencing Analysis of Targeted Lymph Nodes Targeted with Ebola-VLPs 
 Individual sequences of IgG heavy chain variable regions were cloned and 
sequenced from the antigen-targeted whole lymph node mRNA of mice hyper immunized 
with Ebola-VLPs using the same methods described in the previous section for PC-BSA 
immunized mice.  
Analysis of the sequences demonstrates that one of the targeted lymph nodes is 
highly polarized while the other is moderately polarized. Therefore, the antigen-targeted 
lymph nodes of mice hyper-immunized with complex antigen still generate highly 
polarized antibody repertoires. The CD138+ subset was not analyzed because data from 
the PC-BSA immunized mice suggested that the most polarized repertoires would be 
generated from whole lymph node mRNA.  
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Mouse	  5	   Mouse	  6	  
Total	  Number	  of	  Sequences	   32	   41	  
Frequency	  of	  Top	  Heavy	  Chain	   8	   3	  
Top	  Chain,	  %	  total	   25%	   7%	  
Frequency	  of	  Next	  Heavy	  Chain	   1	   2	  
Next	  Most	  Freq	  Chain	  %	  total	   3%	   5%	  
Table 4.4: Frequency of top heavy chains identified from the whole lymph node mRNA 
of two mice immunized repeatedly with Ebola VLPs. Identity was 
determined by identical V(D)J gene usage, identical CDRH3, and less than 3 
nucleotide differences. 
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Figure 4.8: The heavy chain variable sequence from the high frequency antibody generated in Mouse 5 compared to the 
germline sequence. 
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DISCUSSION 
In this work we set to produce the groundwork for a monoclonal antibody 
isolation protocol that improves the speed and simplicity of discovery. Our goal was to 
generate highly polarized antigen specific repertoires of antibodies. We demonstrate that 
a sequence frequency based approach combined with an immunization strategy that 
targets a specific lymph node with a hapten can generate an mRNA population within the 
lymph node in which over 50% of the transcript repertoire encodes for antigen specific 
antibodies. We further report highly polarized libraries following multiple lymph node 
targeted immunizations with the Ebola virus like particles (VLPs).  
In order to target a specific lymph node, we chose to target the popliteal lymph 
node by immunizing in the rear footpad. The popliteal lymph node is an ideal lymph node 
to target because laboratory mice do not commonly experience antigen exposure in the 
footpad. An analysis of PCR products from the cDNA of antigen targeted and non-
targeted popliteal lymph nodes reveals that IgG producing cells are locally restricted to 
the targeted popliteal lymph node (ipsilateral) and these cells are absent in the non-
targeted popliteal lymph node (contralateral). In the more than 20 mice immunized using 
this method, we have never detected IgG via PCR from the non-targeted contralateral 
lymph node. This suggests that the IgG present in the targeted lymph nodes was 
specifically attracted by or generated in response to the node by the immunization. The 
frequency of PC-BSA specific T15 idiotype antibody in repertoires generated in mice 
immunized with PC-BSA suggests that the most frequent IgG variable regions generated 
in this manner are antigen specific.  
The natural frequency of the T15 idiotype is very low in antibody repertoires 
generated from mice not immunized with phosphorylcholine. Analysis of previously 
 116 
collected 454 data shows that among the lymph node plasma cells, only 3 of 16708 
sequences utilize the same V and J combination as T15 (the V gene VHS107.1 is rarely 
used).  Because T15 is normally found as such extremely low frequencies, our analysis of 
the immune response is simplified and we can fairly assume that any T15 presence is a 
response to the phosphorylcholine immunization. This estimation is further supported by 
the lack of T15 idiotype in the spleen plasma cells of mice immunized with 
phosphorylcholine.  
The principle disadvantage of using a simple hapten with a simple monoclonal 
response such as phosphorylcholine is that any principles or strategies derived from such 
a response should be further validated by demonstration with a complicated antigen 
capable of a polyclonal response. We have performed immunizations with Ebola virus 
VLPs in order to demonstrate the strategy is effective for more therapeutically relevant 
immunizations. In order to attain satisfactory titers, mice were immunized four times with 
the antigen and adjuvant. After repeated immunizations and collection of relevant cells 
and mRNA, PCR was used to verify that IgG was localized to the targeting lymph node 
while no detectable IgG was found in the control popliteal lymph node. The localized 
IgG repertoire was also found to contain highly (>20%) or moderately (>5%) frequent 
heavy chain transcripts. This encouraging result implies that this method will likely prove 
useful for multiple immunizations and more complex antigens than phosphorylcholine. 
This encouraging antibody heavy chain is undergoing further analysis with random light 
chains to determine antigen specificity.  
Interestingly, we found that phosphorylcholine specific T15 idiotype was more 
highly represented within the IgG heavy chain repertoire isolated from the total lymph 
node rather than just the CD138+ plasma cells. In both mice that were analyzed, the T15 
idiotype was more than two-fold more frequent in the total lymph node cDNA than the 
 117 
CD138+ subset from the same lymph node. However, an important part of the technology 
developed by Reddy et al. is the use of plasma cells for the identification of antigen 
specific antibodies. Plasma cells are of interest because they are responsible for a 
majority of circulating antibodies and the mechanisms involved in selecting for plasma 
cell differentiation and survival are complex and seem to be partially related to high 
affinity antibodies ((151), (152, 153). Therefore, mining the plasma cell repertoire is 
likely to yield the high affinity antibodies that are responsible for the serum titer. During 
plasma cell differentiation, immunoglobulin mRNA increases to superabundant levels, 
due to both increased transcription and stability of the mRNA (154). Therefore, despite 
the lack of enrichment for CD138+ cells, it is reasonable to suspect that whole lymph 
node isolations are mostly comprised of mRNA transcripts derived from antigen 
secreting cells that are either plasma cell or cells undergoing a transition to becoming 
plasma cells (i.e. plasmablasts).  It then follows that mRNA frequency based antibody 
discovery techniques may be intrinsically biased towards selecting antibodies produced 
by plasma cells.  
The most mature plasma cells are often considered those that have the highest 
level of CD138 and cells with the highest levels of CD138 are found in the bone marrow 
(28). However, B-cell development towards CD138 high plasma cells goes through many 
intermediate steps with low levels of CD138; certain development stages, such as 
plasmablasts, often have a heterogeneous level of CD138 (155). Therefore, developing 
plasma cells, especially the earliest stages of such development, have low or extremely 
low levels of CD138. Enrichment for CD138+ cells from the lymph node excludes many 
of the antigen specific cells being developed in the lymph nodes while enriching for 
irrelevant circulating CD138 high plasma cells found within the lymph node. Our 
evidence suggests that cells found within the targeted lymph node not isolated by 
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CD138+ selection contain an abundance of antigen specific mRNA transcripts, and 
therefore these cells should be included in further studies using lymph node targeting to 
discover antigen-specific antibodies.   
Another possible explanation for the lower representation of T15 heavy chain in 
the CD138+ repertoire is that the other non-T15 idiotype antigen specific antibodies 
dominate the CD138+ population. While we cannot conclusively rule out this possibility, 
we find this unlikely as reports indicate that the primary response to PC should be >90% 
T15 (156). Additionally, neither serum showed significant titer against the carrier protein 
BSA, therefore most antibodies generated as a result of immunization with PC-BSA are 
suspected to be T15 idiotype.  
One complication this work does not address is heavy chain and light chain 
pairing. By immediately lysing the cells upon isolation and relying on the mRNA 
frequency to discovery the relevant antibodies, the link between heavy chain and light is 
destroyed. Therefore, in order to discover antigen specific antibodies, heavy chain and 
light chain pairing must be addressed. While our technology does not directly address this 
issue, we anticipate that the highly polarized libraries generated by this technology will 
make the pairing between heavy chain and light chain of the top antibodies obvious. Even 
though we do not anticipate pairing to be a significant issue, we plan to combine our 
technology with an emerging technology developed within our lab that identifies heavy 
chain and light chain pairs by linking the pairs through single cell PCR. Once these 
methods are combined and refined, we anticipate no significant amount of time should be 
added to the process by solving the pairing problem through sequencing antibodies as 
heavy and light chain pairs.  
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MATERIALS AND METHODS 
Footpad Immunizations 
An emulsion of 1/3 adjuvant (CFA, imject alumn (Thermo, 77161), or Titer Max 
Gold (Sigma T2684-1ml)) with 25ug of antigen (PC-BSA Biosearch Technologies, 
PC1011H-10) in dPBS, pH 7.5 (Thermo, SH30028.02) was prepared at RT by mixing 
with a  pipette then brief sonication until a stable emulsion is achieved (usually 30 
seconds). Injection agent was drawn into the 29G syringe (BD, 309306).  The maximum 
volume that can be injected into a footpad is 30ul (0.05 ml). Only one hind foot was used 
for injection (never inject both hind feet).  Mice were immobilized by scruffing by one 
researcher.  The rear hind foot to be injected was cleaned with water or alcohol to remove 
debris prior to injecting. The second person not scruffing the animal then held the foot 
with one hand and injected the foot subcutaneously using the loaded syringe into the 
center of the hind foot thereby forming a small bleb at the injection site. 
All animals were then closely monitored for signs of pain, food consumption and 
ambulation.  It was not observed in our studies, but there have been reports of self-
mutilation occurring in which the foot is chewed off by the mouse.  This is a sign of 
chronic pain.  Any animal demonstrating self-mutilation should be called to the attention 
of the veterinary staff immediately. The animal must be euthanized when the lesion 
interferes with the animals’ ability to ambulate or reach the food and water.  
 
Titers 
Serum IgG titers were determined by ELISA serial dilution. Briefly, high binding 
ELISA plates (Corning Costar 3590) were coated overnight at 4C with 50ul of 4ug/ml 
antigen in PBS, pH7.5. Plates were aspirated then blocked for 3 hours at 25°C with PBS, 
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pH7.5, 2% milk. Plates were again aspirated then incubated with 50ul of serum diluted 
1/200 through 1/437000 in PBS, pH7.5, 2% milk and incubated at 25°C for 2 hours. 
Plates were washed 3X with PBS, pH 7.5 0.05% tween-20 (PBST) then incubated with 
1/5000 anti-Mouse IgG HRP (Jackson Immuno, 115-065-209) at 25°C for half an hour.  
Plates were washed again 3X with PBST then incubated with 50ul of TMB substrate for 
15 min at 25°C then quenched with 1M sulfuric acid. Plates were read at 450nm and 
analyzed with GraphPad Prism software. Titers were determined as the point where the 
non-linear fitted curve determined 3-fold signal above background.  
 
Cell Subtype Isolation and cDNA amplification 
The isolation procedure described in this section was adapted from Reddy et al. 
and Cato et al. (105, 157). Germinal center cells were not explicitly mentioned in the 
introduction or discussion, but the protocol for their isolation was developed for this 
project and is worth noting.  
Half an hour before sacrifice of immunized mice, 25ul of 2% Evans Blue (Sigma, 
E2129) in PBS, pH 7.5 was injected into both the footpad previously injected with 
antigen and the unimmunized control foot. Sacrifice was performed using carbon dioxide 
according to IAUCUC protocol AUC-2011-00016. Following sacrifice, the skin and fur 
around the leg was removed to reveal the blue stained popliteal lymph node behind back 
of the knee.  The antigen-targeted popliteal lymph node, unimmunized control lymph 
node, and spleen were isolated and collected into buffer 1 (PBS, pH 7.5, 0.1% BSA, 
2mM EDTA) on ice.  
A single cell suspension was made from isolated organs by passing cells through 
a 70uM strainer into a 50mL conical tube (large gauge needles and the rubber stopper of 
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a 3mL syringe are extremely helpful to break up the organ and allow single cells to pass). 
An additional 5ml of Buffer 1 was used to rinse strainer. Cells were then centrifuged at 
500 x g for 10 min in a swinging bucket rotor.  
 
For Spleen Single Cell Suspension: 
Loosened spleen cell pellet was resuspended in 2mL of red blood cell lysis buffer 
(155mM NH4Cl, 12mM NaHCO3, .1mM EDTA in E-pure water) then incubated at 25°C 
for 3.5 min. Following incubation, the lysis reaction was quenched by adding 20mL of 
Buffer 1 at 25°C. Cells were then washed by centrifugation at 500 x g for 10 min at 
25°C, resuspended with 5mL Buffer 1, then centrifuged again. Washed cells were 
resuspend in 1ml Buffer 1, then 200ul of washed spleen suspension were diluted in 300ul 
of Buffer 1 in a 2ml eppendorf at 4°C for further cell subset isolation.  
 
For Lymph Node Single Cell Suspension: 
The entire pellet from the lymph node single cell suspension was resuspended in a 
2ml eppendorf with 0.5mL of Buffer 1 at 4°C. In order to compare antigen-targeted 
proximal lymph node and control distal lymph node, 50ul of proximal lymph node and all 
of distal lymph node were centrifuged and spin down at 500 x g for 10 min at 25°C. Each 
pellet was then resuspended in 400ul of TRI reagent (Ambion AM9738) and stored at -
80°C until mRNA isolation. The remained of the fraction from the antigen-targeted 
lymph node was used for subsequent cell isolation steps outlined in the next sections.   
 
Plasma Cell Isolation For Each 500ul Fraction: 
For each suspension, 1.25ug (2.5ul) of biotin anti-CD138 antibody (BD Pharma, 
553713) was added followed by incubation at 4°C for 20 min while rotating. Cells were 
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then washed twice by centrifugation (500 x g, 10 min, 25°C) and resuspension in 1/2ml 
of ice-cold buffer 1. Following wash, 25ul of preblocked Streptavidin M280 (Invitrogen 
2014-04) beads were added to the suspension then rotated at 4°C for 20min. Next, cell-
bead suspensions were incubated on a DynaMag-2 magnet (Invitrogen, 123-21D) 
followed by incubation at 4°C for 2min. The unbound fraction was removed with pipette 
and used for GC cell isolation protocol described below. Beads and bound cells were 
washed 2X by removing magnet, adding 1mL of buffer 1 at 4°C, applying magnet again, 
and pipetting away buffer 1 and unbound cells. Following wash, 400ul of TRI reagent 
was added to the beads with bound cells then vortexed briefly and stored at -80°C until 
mRNA isolation.  
 
Germinal Center Cell Isolation For Each Pc Depleted 500ul Fraction: 
To each plasma-cell-depleted cell suspension, 6.5ul of biotinylated antibody mix 
was added (antibody mix: 1.25ug biotin anti-CD43 (BD Pharma 553269), 1ug biotin anti-
CD11c (eBioscience 13-0114-82) and 1ug biotin-anti-IgD (eBioscience 13-5593-85)). 
Cell suspension and antibodies were incubated at 4°C for 20 min then washed 2X by 
centrifugation (500 x g, 10min, 25°C) and resuspension in 0.5ml buffer 1 at 4°C. 
Following wash, 20ul of anti-biotin beads (Miltenyi Biotec 120-000-900) were added 
then the mixture was rotated at 4°C for 20min. LS columns were pre-washed (Miltenyi 
Biotec 130-042-401) with 3mL of buffer, and then cell, antibody, and bead mixture was 
added to the LS columns while columns were attached to the provided magnet (Miltenyi 
Biotec 130-090-544). Once the mixture  entered the column, the column was washed 3X 
with 3mL of buffer at 4°C and the flow through was collected. The collected flow 
through was pelleted by centrifuging 500 x g 10 then resuspended in 400ul TRI reagent 
and stored at -80°C until mRNA isolation.  
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Purifying mRNA: 
100ul of chloroform was added to 400ul TRI reagent and vortexed immediately. 
After incubation for 5 min at 25°C, the mixture was centrifuged for 10 min at 12000 x g 
and 4°C. The clear aqueous phase (upper phase) was collected into a new 1.5ml 
eppendorf (~220ul) then 1 volume (200-300ul) of 70% ethanol was added to the mixture 
and vortexed immediately at 25°C. The mixture was added to an RNeasy column (Qiagen 
74004) then centrifuged for 30 seconds at 12000 x g  25°C, followed by a wash with 
500ul of RPE solution (included with RNEasy kit) then 500ul 80% ethanol according to 
manufacturers instructions. Following wash, columns were transfered to a new 2ml 
collection tube (included with RNEasy kit) then centrifuged for 5 min at 12000 x g and 
25°C. Columns were then transferred to a new 1.5ml collection tube included with the 
kit, 20ul RNase free water was added, and then centrifuged for 1 min at 12000 x g and 
25°C. Collected mRNA was then quantified with a Nanodrop instrument according to 
manufacturers instructions.  
 
PCR of cDNA for gel analysis 
cDNA was created from 100ng of mRNA in 20ul reactions with using MMLV-
RT and oligo(dT) according to manufacturers directions from RETROscript kit (Ambion, 
AM1710). Primers for PCR for amplification of the heavy and light chains were designed 
according to the mouse variable gene primer set outlined by Krebber, et al. with Sfi1 sites 
introduced for incorporation into the APEX1 and Mopac16 vectors (158). Individual 
primers were synthesized by IDT, dissolved in E-pure water to 100uM, and mixed 
according to Krebber et al. 1ul of the forward and reverse primer mixtures and 2ul of 
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cDNA were added to standard Phusion polymerase amplification conditions in a 50ul 
PCR reaction. The following PCR conditions were used to amplify cDNA: 
 
Temperature Time (min, seconds) 
98 degC 3,0 
a 4 cycles 
98 degC 0,20 
50 degC 1,0 
72 degC 1,0 
b 4 cycles 
98 degC 0,20 
55 degC 1,0 
72 degC 1,0 
c 4 cycles 
98 degC 0,20 
63 degC 1,0 
72 degC 1,0 
d 16 cycles 
72 degC 7,0 
4 degC forever 
Table 4.5: PCR conditions for the amplification of cDNA with Phusion polymerase and 
variable gene primer sets “VHf” and “IgG constant reverse” 
After completion, PCR reactions were then resolved with a 1% agarose gel 
according to standard DNA electrophoresis conditions. Products at ~350bp were excised 
and used for subsequent analysis.  
For specific amplification of IgG, IgM, T15, or GapDH, primers were designed in 
order to minimize possible overlaps and contaminations from homologous cDNA. 
Amplifications were done according to standard conditions for Phusion polymerase 
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(NEB, M0535L) with 1.5ul cDNA template included in a 50ul reaction. 20 cycles were 
performed with an annealing temperature set to 55°C for 30 seconds followed by a 30 
second extension time at 72°C. After completion, PCR reactions were resolved with a 3% 
agarose gel according to standard DNA electrophoresis conditions. 
 
IgG const for TGACCTGGAACTCTGGATCCCTGTC 
IgG const rev CTGGGACTGTACATATGCAAGGCTTACAAC 
Gapd for GGTGAAGGTCGGTGTGAACG 
Gapdh rev CTCGCTCCTGGAAGATGGTG 
T15 S107f 
TTATTACTCGCGGCCCAGCCGGCCATGGCGCTGGAGTGGATTGCTGCAAGTAGAA
ACAAAGC 
T15 J01r GGCCGCGAATTCGGCCCCCGAGGCCGACTGAGGAAACGGTGACCGTGGTCCCTG 
IgM for CATCCACCTGCTGTGTACCTGCTG 
IgM rev CAACGCAGGTATAGGTCTCTCCGGAG 
Table 4.6: Primers for cDNA analysis from targeted lymph nodes.  
 
Sequencing Analysis 
The frequency of T15 idiotype antibodies from various anatomical compartments 
and cell types was analyzed by amplifying a library of IgG transcripts from a mouse 
immunized via footpad injection with PC-BSA and Titermax Gold. The cDNA from the 
spleen plasma cells, lymph node plasma cells, or whole lymph nodes were amplified 
using the 5’ heavy chain primer set “VHfor” based on designed from Krebber et al. and 
3’ heavy chain “IgG constant reverse” primers that amplify IgG1, 2a, 2b and 3 (158). 
Each primer from the “VHfor” set was resuspended in purified water to 100uM and 
mixed according to the table below.  
  
 126 
 
 Name	   Sequence	   %	  in	  mix	  FOR	  1	   ATGGCCCAGCCGGCCATGGCGGAKGTRMAGCTTCAGGAGTC	   7.6%	  FOR	  2	   ATGGCCCAGCCGGCCATGGCGGAGGTBCAGCTBCAGCAGTC	   7.6%	  FOR	  3	   ATGGCCCAGCCGGCCATGGCGCAGGTGCAGCTGAAGSASTC	   5.7%	  FOR	  4	   ATGGCCCAGCCGGCCATGGCGGAGGTCCARCTGCAACARTC	   7.6%	  FOR	  5	   ATGGCCCAGCCGGCCATGGCGCAGGTYCAGCTBCAGCARTC	   13.2%	  FOR	  6	   ATGGCCCAGCCGGCCATGGCGCAGGTYCARCTGCAGCAGTC	   3.8%	  FOR	  7	   ATGGCCCAGCCGGCCATGGCGCAGGTCCACGTGAAGCAGTC	   1.9%	  FOR	  8	   ATGGCCCAGCCGGCCATGGCGGAGGTGAASSTGGTGGAATC	   3.8%	  FOR	  9	   ATGGCCCAGCCGGCCATGGCGGAVGTGAWGYTGGTGGAGTC	   9.5%	  FOR	  10	   ATGGCCCAGCCGGCCATGGCGGAGGTGCAGSKGGTGGAGTC	   3.8%	  FOR	  11	   ATGGCCCAGCCGGCCATGGCGGAKGTGCAMCTGGTGGAGTC	   3.8%	  FOR	  12	   ATGGCCCAGCCGGCCATGGCGGAGGTGAAGCTGATGGARTC	   3.8%	  FOR	  13	   ATGGCCCAGCCGGCCATGGCGGAGGTGCARCTTGTTGAGTC	   1.9%	  FOR	  14	   ATGGCCCAGCCGGCCATGGCGGARGTRAAGCTTCTCGAGTC	   3.8%	  FOR	  15	   ATGGCCCAGCCGGCCATGGCGGAAGTGAARSTTGAGGAGTC	   3.8%	  FOR	  16	   ATGGCCCAGCCGGCCATGGCGCAGGTTACTCTRAAAGWGTSTG	   9.5%	  FOR	  17	   ATGGCCCAGCCGGCCATGGCGCAGGTCCAACTVCAGCARCC	   6.6%	  FOR	  18	   ATGGCCCAGCCGGCCATGGCGGATGTGAACTTGGAAGTGTC	   1.3%	  FOR	  19	   ATGGCCCAGCCGGCCATGGCGGAGGTGAAGGTCATCGAGTC	   1.3%	  
Table 4.7: The primer mix derived from Krebber et al. with 5’ sfi site added 
Each of the primers from IgG rev set described in the table below were diluted to 
100uM each and a mix of the four primers at a 1:1:1:1 ratio created “IgG constant 
reverse” primer mix. 
 
SC-IgG1-constrev TTCGGCCCCCGAGGCCGAGCCAGAGTTCCAGGTCACTGTCACTG 
SC-IgG2a-constrev TTCGGCCCCCGAGGCCGAGCCAGAGTTCCAGGTCAAGGTCACTG 
SC-IgG2b-constrev TTCGGCCCCCGAGGCCGAGCCAGAGTTCCAAGTCACAGTCACTG 
SC-IgG3-constrev TTCGGCCCCCGAGGCCGAGCCATAGTTCCATTTTACAGTTACCG 
Table 4.8: Reverse primers designed to amplify IgG1,2a,2b and 3. 
cDNA was amplified with 1.5ul cDNA, 1ul of each forward and reverse primer 
mix, and the standard Phusion polymerase amplification conditions for a 50ul reaction 
(table 3.4). The reaction was performed via the PCR cycle described in the previous 
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section. Following amplification, the PCR reaction was resolved using standard 
electrophoresis conditions with a 1% agarose gel, then the ~450bp DNA band was 
excised and purified. Purified insert was digested using standard sfi1 conditions, followed 
by PCR cleanup then ligation into the pak200 vector. Ligations were transformed into 
Jude1 cells. Following overnight growth at 37°C on selective plates, individual colonies 
were selected and sequenced using standard Sanger sequencing.  
The sequence for the T15 idiotype was compiled from the following publications 
(149, 150).  
 
 
Figure 4.9: T15 DNA sequence, protein translation and V-D-J usage compiled from 
previous publications (149, 150).  
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DNA analysis software (Geneious Pro 5.4.6) was then employed to determine 
sequence homology to the established T15 sequence (Figure 3.9). Matches were 
determined by identical usage of V-D-J genes and identical CDRH3 sequences. 
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Chapter 5 
Conclusions 
The work detailed in this manuscript has resulted in the isolation of a high affinity 
antibody D, the first antibody shown to inhibit classical complement activity by 
inhibiting the C1s protease on the C1 complex. The disregulation of classical 
complement activation is associated with numerous human diseases including rheumatoid 
arthritis, transplant rejection, ischemic reperfusion injury and neurological disorders; 
therefore the regulation of this pathway is highly desirable. In order to discover antibody 
D, novel protocols and strategies were used for discovery and characterization. Extensive 
assay development was done with a focus on creating cell and plate based assays to 
demonstrate antibody D can regulate classical complement when the pathway is 
selectively activated by surface bound immunoglobulin. Through novel classical 
complement inhibition assays, we demonstrated the first example of an antibody that 
specifically regulates the classical complement pathway by targeting the C1s protease on 
the pathway initiating C1-complex. 
It is further shown that affinity maturation of antibody D results in higher levels 
of complement inhibition at various antibody concentrations. The affinity-matured 
variant was only a 2-fold improvement over the parental antibody, but inhibition of 
classical complement activity was improved in all three assays we developed. We 
therefore assume that further affinity maturation should be pursued in the future in order 
to further increase the effectiveness of the antibody. However, we experienced great 
difficulty affinity maturing antibody D, while other studies performed using similar 
methods achieved much greater affinity improvement (>200 fold in some cases). The 
difficult in achieving a significant enhancement in the affinity of antibody D may be due 
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to its unusually long CDR3, which may be important for binding to the active site, cleft 
of C1s. In this case, further affinity improvements may need introducing mutations within 
the CDRH3 loop in order further optimize the contact interface.  
The most significant limitation of antibody D and its affinity matured mutant 
D.35 is the high concentrations required to achieve ~50% inhibition of complement 
activity (>5uM in our studies).  Even with a further affinity matured antibody D variant, 
it may be difficult to inhibit classical complement activity completely at more 
therapeutically relevant antibody concentrations (<1uM). In order to address the 
exceedingly high concentration of FAB D.35 inhibitor required for complement inhibition, 
a combination of antibody inhibitors might be a desirable approach to limit complement 
activation at lower antibody concentrations. It is therefore particularly relevant that we 
have shown novel methodologies for discovering and affinity maturing such antibodies 
that can be easily tailored to different classical complement proteins or an entirely 
different pathway. Alternative antibody-based classical complement inhibition strategies 
that prevent C1 complex signaling could be developed by slightly modifying our 
discovery scheme for development of antibodies that bind the proenzyme form of C1s or 
C1r.  
 Another important aspect of the work detailed in this manuscript was the 
characterization of the lymphocytes and immune responses in humanized NSG 
((NOD.Cg-Prkdcscid  Il2rgtm1Wjl/SzJ ) mice at 6- and 12-weeks post-engraftment. Humanized 
mice are generated through the engraftment of human CD34+ hematopoietic stem cells 
into immune-deficient mice. Once engrafted, the human stem cells home in to the bone 
marrow where they divide and differentiate into human cells of the myeloid and 
lymphoid lineages. Humanized mice are particularly relevant because they provide an 
important preclinical model that enables the investigation of human-specific infectious 
 131 
diseases, most notably human-specific diseases such as HIV, Dengue virus and Epstein-
Barr virus (EBV).  
In order to better understand the model, we sought to characterize the human 
immune cells produced by humanized NSG mice, most notably the B and T lymphocytes, 
post-engraftment with human CD34+ HSC cells. We detected development of naïve 
human B and T cells and their various subtypes, as well as other human immune cells 
from engrafted mice. However, attempts to generate a robust antibody response to 
antigens were unsuccessful. Therefore, we conclude that NSG humanized mice 
developed in this study are suitable for studying the naïve B cells, however they are not 
suitable for the analysis of activated B-cells.  
One reason thought to be partially responsible for the weak antibody response is 
that human T cell selection occurs against murine MHC I / II thereby altering human T 
cell help to mature B lymphocytes (1). It is important to determine all potential deviations 
humanized mice lymphocytes may have from their normal human counterpart that might 
impact the relevance of humanized mouse as a model for the study of human immune 
cells in vivo. Previous accounts describing the mature naïve B cell subsets generated in 
NSG humanized mice have not thoroughly characterized the B cell antibody repertoires 
in depth. One aspect that may deviate from normal human characteristics is the repertoire 
of antibodies produced by the naïve mature B cells and the active B cell immune 
response. In subsequent studies the mature naïve B cell population was sequenced and 
analyzed and it was determined that it was chiefly indistinguishable from those in human 
blood cells (2).  
Last, we introduced a novel strategy for the generation of polarized antibody 
repertoires for use in therapeutic monoclonal antibody discovery. Reddy et al. showed 
that the most abundant antibody V genes (.5-10% frequency) expressed by bone marrow 
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plasma cells (BM-PCs) 7 days post-boost immunization correspond to antigen-specific 
antibodies. However, not all highly frequency V genes in the BM-PC repertoire are 
antigen specific necessitating the testing of several combinations of the most frequent VH 
and VL genes to find antibodies with desired affinity and specificity. Therefore, we 
sought to develop a technique that would isolate more polarized repertoires with many 
antigen specific antibodies and less irrelevant ones. Our technique for repertoire isolation 
involved targeted antigen delivery to a specific lymph node and isolation of that 
particular lymph node repertoire. Lymph nodes do not hold long-lived plasma cells, and 
therefore we expected less plasma cells producing irrelevant antibody.  
Following primary footpad immunization of two BALB/c mice with a small 
hapten (phosphorylcholine conjugated to BSA), we used PCR and Sanger sequencing of 
the antibody variable genes to investigate the repertoire of antibodies found in the 
targeted popliteal lymph node. Sequencing of the heavy chain V-gene repertoire revealed 
that mRNA transcripts isolated from the antigen-targeted lymph nodes were >20% of 
antibodies in known idiotype (T15) that specifically binds the hapten. When two 
additional mice were repeatedly immunized with a more complex antigen (Ebola virus 
like particles), Sanger sequencing analysis of the antigen targeted lymph nodes revealed a 
highly polarized repertoire in one mouse ( >20% of the antibodies corresponded to one 
heavy chain sequence) and a moderately polarized repertoire in another mouse ( >5%).  
We expect that this work will be the foundation of an overall improved protocol 
for monoclonal antibody discovery that accelerates the speed and enhances the simplicity 
of discovery techniques. Both of these repertoires were highly polarized and therefore 
accomplished our goals, however, future work should focus on the validation of these 
highly polarized libraries by making the antibodies for the polarized repertoire in order to 
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determine their specificity. The combination of polarized repertoires with confirmed 
antigen specificity is currently undergoing further study.  
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Appendix 1 
Modeling Inhibition of C1s and Classical Complement by Antibody D 
 
INTRODUCTION 
Antibody D and its affinity-maturated variant D.35 described in Chapter 2 inhibit 
classical complement activity by inhibiting the C1s protease of the biochemical cascade. 
However, the concentrations of antibody required to inhibit the classical complement are 
much too high in order to be considered a serious therapeutic candidate. In the results of 
Chapter 2, we establish that affinity maturation of antibody D increases complement 
inhibition at the same concentrations. Furthermore, we established that the ~10-fold 
relative affinity increase via changing antibody format from fAb to IgG also increases the 
relative inhibition of C1s proteolysis of its substrate C2. Therefore, it is conceivable that 
further affinity maturation would lead to increased complement inhibition. In this work, 
we set to modeling the interaction between antibody and C1s to predict the dissociation 
constant necessary for inhibition of complement at therapeutically relevant antibody 
concentrations.  
 
RESULTS 
Modeling C1s inhibition by an Antibody Predicts Affinity Goals for further D 
Improvement  
The mathematical model described in the materials and method section can 
predict substrate cleavage levels for a given set of inputs (time, KD, concentrations, etc). 
In order to validate the model, it was used to predict outcomes for scenarios tested 
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experimentally. Once validated, it was then used to predict dissociation constants 
required for therapeutic effectiveness at physiological conditions.  
 
Validating Mathematical Model using Experimental Results 
Experimental conditions that are easily measured by SDS-PAGE were used in 
order to test the predictive abilities of the model. These experimental results were 
overlaid with the predicted outcomes for the same conditions with an antibody of various 
dissociation constants in the figure below (A.1).  
 
 
Figure A.1: Experimental Results Overlaid with Model Predictions 
The inhibitor FAB D has been shown to have a KD = 1.7nM and the model 
accurately predicts the amount of substrate remaining for an antibody inhibitor with 
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roughly that concentration. These results confirm that the model can accurately predict 
the impact of a reversible inhibitor on C1s and substrate with user-defined inputs.   
 
Employing Mathematical Model to Set KD Goal for Therapeutic Relevance 
Once the validity of the model was confirmed, the inputs were then changed to 
represent the actual concentrations in vivo. In order to determine the dissociation constant 
of an antibody necessary for inhibition of the classical complement at physiological 
substrate and enzyme concentrations, three important questions were proposed:  
1. What is the expected serum concentration of a therapeutic antibody? 
2. What is the acceptable free enzyme concentration required for inhibition 
of the entire pathway?  
3. What Kd does antibody D need to have in order to achieve this level of 
inhibition at physiological conditions? 
 
The first question was answered by reviewing the monoclonal antibody package 
inserts that come with such drugs as Herceptin. A review of published clinical 
information concerning therapeutic antibody serum concentrations found that the most 
common antibody trough concentration was ~660nM (159). Thus we can expect that a 
monoclonal IgG would need to be effective at this concentration. The model will 
ultimately be used to determine what dissociation constant will inhibit complement 
activity at 660nM of therapeutic antibody. 
The model is able to determine the amount of C1s activity in the presence of an 
inhibitory antibody. However, it does not determine the level of C1s activity that is 
acceptable in order to effectively stop classical complement mediated cell lysis. In order 
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to determine the maximum acceptable active free C1s enzyme level that does not result in 
cell lysis, the free active enzyme predicted by the model is compared to the 
experimentally determined classical complement mediated lysis of RAMOS cell under 
the same conditions. The overlaid graph is shown below (figure A2)    
 
 
Figure A.2: Comparison of free enzyme (nM) predicted by model and experimentally 
determined fraction Ramos Cells lysed at simiar antibody concentrations.  
In order to maintain cell integrity, the model predicts that ~25pM of C1s can be 
unbound by antibody and the cells will still maintain their integrity. Next different 
dissociation constants were modeled in order to predict the KD necessary to achieve only 
.025nM free C1s enzyme with 660nM of antibody.  
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Figure A.3: Predicted free enzyme for antibodies with different dissociation constants 
and 660nM antibody (vertical blue line) and serum concentrations of other 
components. Horizontal blue line indicates .025nM free C1s goal.  
An antibody with at least .01nM dissociation constant achieves .025pM of free 
C1s at 660nM. Therefore, according the model, an antibody that binds the same epitope 
as antibody D with a dissociation constant of .01nM will inhibit classical complement 
mediated lysis of RAMOS cells at therapeutically relevant concentrations.. This is the 
goal for future C1s inhibiting antibody dissociation constant.  
 
DISCUSSION 
The target dissociation constant for further affinity maturation was determined 
using the model herein described. While simplifying assumptions may flaw the model 
(listed in M&M), linking the experimental results to the model compensates for 
erroneous assumptions. Therefore, we confidently set the experimental goal of 10pM 
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dissociation constant in order to inhibit classical complement activity at therapeutic 
concentrations.  
The goal determined from the model, 10pM KD, may be attained in a number of 
ways: through the increase in apparent affinity associated with bivalency, through 
discovery of a new higher affinity antibody, or further affinity maturation. The difficulty 
in discovering another antibody that binds and inhibits the C1s enzyme is a daunting task 
because the antibody discovery techniques do not necessarily discover antibodies that 
both bind and inhibit C1s. Therefore the process could take an exceedingly long time to 
uncover the antibody with no guarantee that the antibody will have a higher affinity. 
Instead, antibody D.35 should be further improved by the strategies of affinity maturation 
and apparent affinity increase associated with bivalency. 
 
MATERIALS AND METHODS 
Mathematical Modeling of C1s Inhibition 
The following is the derivation of the model for a system in which an antibody 
inhibits an enzyme by reversible binding. This section will derive the underlying 
equations for this model using constants that can be substituted for any enzyme-antibody-
substrate system.  The underlying assumption of this system is the antibody is a steric 
inhibitor; therefore enzyme bound by an antibody is not able to perform an enzymatic 
reaction. There are two important components to this model: enzyme kinetics that 
governs the rate of substrate proteolysis and reversible binding thermodynamics that 
governs the amount of free enzyme available for kinetic reactions.  These two 
components are independently modeled, then combined.  
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Modeling Kinetic Parameters: Proteolysis 
In order to model the impact of inhibitory antibodies on C1s, it is first necessary 
to model substrate C2 or C4 proteolysis in the absence of any inhibitor. This is commonly 
done in chemical engineering using Michaelis-Menten kinetic model of enzymes. This 
model is the best-known model of enzyme kinetics and relies on the assumption that 
enzymes form a reversible complex with their substrate before catalyzing an irreversible 
enzymatic reaction(160, 161). The Michaelis-Menten model is written as follows: 𝐸 + 𝑆 ⇌ 𝐸𝑆⟶ 𝐸 + 𝑃  
Where E is the enzyme concentration, S is the substrate concentration and P is the 
product concentration. For the interaction modeled in this work, E is C1s, S is one of the 
C1s substrates C2 or C4, and P is the cleaved substrate concentration. This model can be 
expressed mathematically in terms of rate constants and product concentrations. The 
model is commonly used in textbooks to derive the Michaelis-Menten kinetic equation:  
 
KM is the Michaelis-Menten constant, and kcat is the turnover number; each of 
these numbers is a property of the enzyme and can be found in the BRENDA enzyme 
database. This model assumes the substrate is in instantaneous chemical equilibrium with 
the complex. This equation can be solved to express the free enzyme concentration (i.e. 
not in complex with substrate) as a function of substrate concentration and time: 
 
v0 =
vmax[S]
[S]+KM
=
kcat[E][S]
[S]+KM
=
∂S
∂t
[E]=
[S0 ]−[S]+KM ln([S0 ][S] )
kcatt
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With this equation it is possible to model the fraction of substrate remaining after 
a set time (50mins in this case) as a function of free enzyme concentration.  
 
Modeling Thermodynamic Parameters:  
The other component of this model is the interaction between enzyme and 
antibody (C1s and D) that inhibits the ability of the enzyme to proteolyze substrate.  In 
the case of an inhibitory reversible binder, such as antibody D, the free enzyme 
concentration is based on thermodynamic equilibrium. When the antibody binds the 
enzyme, it is not free to proteolyze substrate. Unbound enzyme is called “free enzyme” 
and is available to proteolyze substrate. The thermodynamic equilibrium can be 
expressed in terms of the dissociation constant and written in the following manner:  
 
E0 is the total enzyme in solution, F0 is the total antibody in solution, and X is the 
concentration of the antibody-enzyme complex. For simplicity, it is assumed the antibody 
is monovalent FAB, which is true of the experiments performed in this study. This 
equation is rearranged to solve for the concentration of the antibody-enzyme complex, X: 
 
The antibody-enzyme complex can be expressed in terms of the “free enzyme 
concentration”, [E]: 
[E]+[X] = [E0] 
Combining these two equations expresses the thermodynamic term in terms of 
initial conditions and the free enzyme concentration.  
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Combined Parameters and Modeling in Excel 
The combining the kinetic and thermodynaic equations from the previous two 
subsections allows for expression of the substrate concentration over time in terms of 
known input values such as kcat, KM, substrate initial concentration, total antibody 
concentration, total enzyme concentration and the dissociation constant KD. In order to 
use these values and model scenarios of interest, an excel file is built that first determines 
“free enzyme” concentration using the thermodynamic equations. The free enzyme 
concentration is then used as an input for the kinetic equation. This model can then be 
used to predict various outputs from defined input conditions. The most useful output 
parameter is the substrate concentration, [S]; however it is difficult to solve for this 
parameter using the final kinetic equation. Instead the excel file is set up such that [S] is 
an input and the output is time, a much simpler parameter to solve for. In order to 
determine the substrate concentration [S] at a given time, the Goal Seek function is 
employed to seek the substrate concentration present at a given time. For example, using 
the kinetic constants for C1s (enzyme) towards C2 (substrate) and known input 
concentrations of enzyme, substrate and inhibitor, the impact of the dissociation constant 
KD can be determined on the amount of substrate cleaved in 50 minutes.   
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Figure A.4: Example output of model for various dissociation constants 
In this example, it is clear that for the given inputs the dissociation constant 
impacts substrate cleavage dramatically at a 5-fold antibody to enzyme ratio. The 
dissociation constant does not have a significant impact when large excess of either 
component is present. For a given amount of substrate cleavage in 50 minutes, a lower 
dissociation constant (higher affinity) results in less inhibitor required. Sample inputs are 
shown in the table below, including the enzyme constants from BRENDA enzyme 
database that are used for all scenarios.  
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kcat	  (1/s)	  
	  
5.1	  
Km	  (nM)	  
	  
6100	  
C2	  init	  conc	  (nM)	   So	   3000	  
C2	  final	  conc	  (nM)	   S	   826.574296	  
Free	  Enzy	  conc	  (nM)	   E	   0.656	  
time	  (sec)	   t	   3000.000016	  
Frac	  Cleaved	   S/So	   0.275524765	  
50	  mins	  =	  3000	  sec	  
	   	  
Table A.1: Example Inputs for Model 
Assumptions Inherent in the Model 
The model makes many simplifying assumptions.  
1. C2 and C4 can be modeled as one substrate.  
2. C1s is free floating in a solution, instead of immobilized to a surface 
bound antibody 
3. The two C1s molecules present in the C1 complex can be assumed to be 
two C1s molecules free floating in solution 
4. All available C1s is activated 
 
The first assumption, that substrates C2 and C4 can be modeled as one substrate, 
is acceptable because the kcat and KM of C1s for these substrates is nearly identical. The 
other simplifying assumptions are necessary for simplicity. In the results section, the 
model will be linked to real-world data in order to compensate for any resulting flaws 
from these assumptions.  
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